56 results on '"Vincent Hayes"'
Search Results
2. Enhancing functional platelet release in vivo from in vitro–grown megakaryocytes using small molecule inhibitors
- Author
-
Danuta Jarocha, Karen K. Vo, Randolph B. Lyde, Vincent Hayes, Rodney M. Camire, and Mortimer Poncz
- Subjects
Specialties of internal medicine ,RC581-951 - Abstract
Abstract: In vitro–grown megakaryocytes for generating platelets may have value in meeting the increasing demand for platelet transfusions. Remaining challenges have included the poor yield and quality of in vitro–generated platelets. We have shown that infusing megakaryocytes leads to intrapulmonary release of functional platelets. A Src kinase inhibitor (SU6656), a Rho-associated kinase inhibitor (Y27632), and an aurora B kinase inhibitor (AZD1152) have been shown to increase megakaryocyte ploidy and in vitro proplatelet release. We now tested whether megakaryocytes generated from CD34+ hematopoietic cells in the presence of these inhibitors could enhance functional platelet yield following megakaryocyte infusion. As expected, all inhibitors increased megakaryocyte ploidy, size, and granularity, but these inhibitors differed in whether they injured terminal megakaryocytes: SU6656 was protective, whereas Y27632 and AZD1152 increased injury. Upon infusion, inhibitor-treated megakaryocytes released threefold to ninefold more platelets per initial noninjured megakaryocyte relative to control, but only SU6656-treated megakaryocytes had a significant increase in platelet yield when calculated based on the number of initial CD34+ cells; this was fourfold over nontreated megakaryocytes. The released platelets from drug-treated, but healthy, megakaryocytes contained similar percentages of young, uninjured platelets that robustly responded to agonists and were well incorporated into a growing thrombus in vivo as controls. These studies suggest that drug screens that select megakaryocytes with enhanced ploidy, cell size, and granularity may include a subset of drugs that can enhance the yield and function of platelets, and may have clinical application for ex vivo–generated megakaryocytes and platelet transfusion.
- Published
- 2018
- Full Text
- View/download PDF
3. Loss of ATE1-mediated arginylation leads to impaired platelet myosin phosphorylation, clot retraction, and in vivo thrombosis formation
- Author
-
Lurong Lian, Aae Suzuki, Vincent Hayes, Sougata Saha, Xuemei Han, Tao Xu, John R Yates, Mortimer Poncz, Anna Kashina, and Charles S. Abrams
- Subjects
Diseases of the blood and blood-forming organs ,RC633-647.5 - Abstract
Protein arginylation by arginyl–transfer RNA protein transferase (ATE1) is emerging as a regulator protein function that is reminiscent of phosphorylation. For example, arginylation of β-actin has been found to regulate lamellipodial formation at the leading edge in fibroblasts. This finding suggests that similar functions of β-actin in other cell types may also require arginylation. Here, we have tested the hypothesis that ATE1 regulates the cytoskeletal dynamics essential for in vivo platelet adhesion and thrombus formation. To test this hypothesis, we generated conditional knockout mice specifically lacking ATE1 in their platelets and in their megakaryocytes and analyzed the role of arginylation during platelet activation. Surprisingly, rather than finding an impairment of the actin cytoskeleton structure and its rearrangement during platelet activation, we observed that the platelet-specific ATE1 knockout led to enhanced clot retraction and in vivo thrombus formation. This effect might be regulated by myosin II contractility since it was accompanied by enhanced phosphorylation of the myosin regulatory light chain on Ser19, which is an event that activates myosin in vivo. Furthermore, ATE1 and myosin co-immunoprecipitate from platelet lysates. This finding suggests that these proteins directly interact within platelets. These results provide the first evidence that arginylation is involved in phosphorylation-dependent protein regulation, and that arginylation affects myosin function in platelets during clot retraction.
- Published
- 2014
- Full Text
- View/download PDF
4. Abstract 6200: PARP1 hyperactivation by the decoy oligodeoxynucleotide OX425 mediates DNA repair abrogation and unleashes the anti-tumor immune response
- Author
-
Vlada Zakharova, Claudia Galassi, Chloé Doizelet, Vincent Hayes, Lorenzo Galluzzi, and Wael Jdey
- Subjects
Cancer Research ,Oncology - Abstract
Background: Poly (ADP-ribose) polymerase inhibitors (PARPis) lead to synthetic lethality when used in cancers with homologous recombination deficiency (HRD). However, the development of resistance to PARPis is a recurrent problem thus limits the duration of response and hence the clinical utility of these agents. Here, we describe the antineoplastic and immunomodulatory effects of OX425, a first-in-class oligodeoxynucleotide that operates as a PARP1 decoy, resulting in constitutive PARP1 hyperactivation and consequent exhaustion of the DNA damage response. Methods: OX425-induced PARP trapping, hyperactivation and cell cytotoxicity were examined in vitro in HRD and homologous recombination proficient (HRP) human cancer cells, as well as in non-transformed cell lines. DNA repair efficacy was monitored by analyzing repair protein recruitment to damage sites. OX425 effects on the innate and adaptive immune responses were assessed by following STING activation and T-cell mediated anti-tumor cytotoxicity. RNAseq analysis in HRP/HRD tumor cells treated with OX425 or PARP inhibitors was employed to uncover the molecular mechanisms underlying OX425 effects. The anticancer efficacy of OX425 was assessed in vivo in different HRD and HRP tumor models. OX425-induced PARP activation and tumor infiltration by immune cells were analyzed by flow cytometry. Results: At odds with conventional PARP inhibitors, OX425 bound to and hyperactivated PARP1 with high affinity in a dose-dependent manner, resulting in elevated cytotoxicity to multiple cancer cells (breast, ovarian, prostate, colon, hematological, endometrial cancers) irrespective of HR status. Interestingly, long-term treatment with OX425 did not show any mutagenicity compared to PARPi. The activity of OX425 was specific to tumor cells, as no significant effect on cell viability was observed for normal cells, at odds with PARP inhibitors. In line with in vitro results, OX425 mediated considerable anticancer effects in vivo. Moreover, OX425 triggered activation of the STING pathway and CCL5 secretion in the EMT6 mouse mammary carcinoma model. The anticancer effect of OX425 was coupled with tumor-targeting T cell responses. In MPA/DMBA-driven mammary tumors, OX425 mediated considerable anticancer effects in monotherapy and synergistic effects in combination with PD1 inhibition. Moreover, OX425 treatment significantly delayed acquired resistance to olaparib in BRCA1 mutated MDA-MB-436 cell-derived xenografts. Conclusions: Our results provide preclinical rationale for using OX425 to trigger DNA damage exhaustion and STING activation in cancer cells and initiate inflammatory responses that can be actioned by immune checkpoint inhibitors in patients bearing HRD or HRP tumors Citation Format: Vlada Zakharova, Claudia Galassi, Chloé Doizelet, Vincent Hayes, Lorenzo Galluzzi, Wael Jdey. PARP1 hyperactivation by the decoy oligodeoxynucleotide OX425 mediates DNA repair abrogation and unleashes the anti-tumor immune response [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr 6200.
- Published
- 2023
5. Structure-guided design of pure orthosteric inhibitors of αIIbβ3 that prevent thrombosis but preserve hemostasis
- Author
-
M. Amin Arnaout, I-Shing Yu, Shu-Wha Lin, Vincent Hayes, Johannes van Agthoven, Brian D. Adair, Hyun Sook Ahn, Mortimer Poncz, José Luis Alonso, and Jian-Ping Xiong
- Subjects
0301 basic medicine ,Male ,Platelet Aggregation ,General Physics and Astronomy ,030204 cardiovascular system & hematology ,Pharmacology ,Mice ,0302 clinical medicine ,Medicine ,Platelet ,Gene Knock-In Techniques ,lcsh:Science ,media_common ,Multidisciplinary ,biology ,Recombinant peptide therapy ,Drug discovery ,Tirofiban ,Thrombosis ,Healthy Volunteers ,3. Good health ,Structural biology ,medicine.drug ,Drug ,Platelet Function Tests ,Science ,media_common.quotation_subject ,Integrin ,Hemorrhage ,Mice, Transgenic ,Clot retraction ,Platelet Glycoprotein GPIIb-IIIa Complex ,Biologics ,Partial agonist ,General Biochemistry, Genetics and Molecular Biology ,Article ,03 medical and health sciences ,Structure-Activity Relationship ,von Willebrand Factor ,Animals ,Humans ,Blood Coagulation ,X-ray crystallography ,business.industry ,General Chemistry ,medicine.disease ,Platelet Activation ,Disease Models, Animal ,030104 developmental biology ,Hemostasis ,Drug Design ,biology.protein ,lcsh:Q ,business ,K562 Cells ,Peptides ,Platelet Aggregation Inhibitors - Abstract
A prevailing dogma is that inhibition of vascular thrombosis by antagonizing platelet integrin αIIbβ3 cannot be achieved without compromising hemostasis, thus causing serious bleeding and increased morbidity and mortality. It is speculated that these adverse outcomes result from drug-induced activating conformational changes in αIIbβ3 but direct proof is lacking. Here, we report the structure-guided design of peptide Hr10 and a modified form of the partial agonist drug tirofiban that act as “pure” antagonists of αIIbβ3, i.e., they no longer induce the conformational changes in αIIbβ3. Both agents inhibit human platelet aggregation but preserve clot retraction. Hr10 and modified tirofiban are as effective as partial agonist drugs in inhibiting vascular thrombosis in humanized mice, but neither causes serious bleeding, establishing a causal link between partial agonism and impaired hemostasis. Pure orthosteric inhibitors of αIIbβ3 may thus provide safer alternatives for human therapy, and valuable tools to probe structure–activity relationships in integrins., Current inhibitors of platelet integrin αIIbβ3 cause excessive bleeding, which limited their clinical use in cardiac patients. Here the authors design pure orthosteric αIIbβ3 inhibitors that prevent platelet aggregation and thrombosis without causing bleeding in humanized mouse models of thrombosis
- Published
- 2020
6. Epithelial (E)-Cadherin is a Novel Mediator of Platelet Aggregation and Clot Stability
- Author
-
Vanessa M Scanlon, Michael S. Marks, Jialing Bao, Mortimer Poncz, M. Anna Kowalska, Siying Zou, Ping-Xia Zhang, Alexandra M. Teixeira, Tarun Tyagi, Vincent Hayes, Carmen J. Booth, Diane S. Krause, and John Hwa
- Subjects
Blood Platelets ,0301 basic medicine ,Bleeding Time ,Platelet Aggregation ,Integrin ,Mice, Transgenic ,Clot retraction ,030204 cardiovascular system & hematology ,Article ,Mice ,03 medical and health sciences ,chemistry.chemical_compound ,0302 clinical medicine ,Thrombin ,Conditional gene knockout ,Cell Adhesion ,medicine ,Animals ,Humans ,Platelet ,Blood Coagulation ,Protein kinase B ,Cells, Cultured ,Mice, Knockout ,biology ,Chemistry ,Thrombosis ,Hematology ,Cadherins ,Cell biology ,Mice, Inbred C57BL ,Adenosine diphosphate ,030104 developmental biology ,Liver ,Knockout mouse ,biology.protein ,Megakaryocytes ,Signal Transduction ,medicine.drug - Abstract
Cadherins play a major role in mediating cell–cell adhesion, which shares many parallels with platelet–platelet interactions during aggregate formation and clot stabilization. Platelets express epithelial (E)-cadherin, but its contribution to platelet function and/or platelet production is currently unknown. To assess the role of E-cadherin in platelet production and function in vitro and in vivo, we utilized a megakaryocyte-specific E-cadherin knockout mouse model. Loss of E-cadherin in megakaryocytes does not affect megakaryocyte maturation, platelet number or size. However, platelet dysfunction in the absence of E-cadherin is revealed when conditional knockout mice are challenged with acute antibody-mediated platelet depletion. Unlike wild-type mice that recover fully, knockout mice die within 72 hours post-antibody administration, likely from haemorrhage. Furthermore, conditional knockout mice have prolonged tail bleeding times, unstable clot formation, reduced clot retraction and reduced fibrin deposition in in vivo injury models. Murine platelet aggregation in vitro in response to thrombin and thrombin receptor activating peptide is compromised in E-cadherin null platelets, while aggregation in response to adenosine diphosphate (ADP) is not significantly different. Consistent with this, in vitro aggregation of primary human platelets in response to thrombin is decreased by an inhibitory E-cadherin antibody. Integrin activation and granule secretion in response to ADP and thrombin are not affected in E-cadherin null platelets, but Akt and glycogen synthase kinase 3β (GSK3β) activation are attenuated, suggesting a that E-cadherin contributes to aggregation, clot stabilization and retraction that is mediated by phosphoinositide 3-kinase/Akt/GSK3β signalling. In summary, E-cadherin plays a salient role in platelet aggregation and clot stability.
- Published
- 2019
7. Abstract 2600: AsiDNA® treatment protects healthy cells from anticancer treatment toxicity
- Author
-
Wael Jdey, Anouk Sesink, Agathe Cohendet, Juliette Rieu, Chloe Doizelet, Vincent Hayes, Pierre-Marie Girard, Marie Dutreix, and Judith Greciet
- Subjects
Cancer Research ,Oncology - Abstract
Purpose: Conventional cytotoxic therapies are still the standard of care for the treatment of many cancers. However, the associated severe side effects, especially damage to normal proliferating cells like stem and progenitor cells, often lead to drug dose reduction, which limits treatment success. Indeed, chemotherapy-induced myelosuppression is manifested by neutropenia, lymphopenia, anemia, and thrombocytopenia. Although growth factors ameliorate this myelosuppression, their efficacy is still suboptimal and lineage specific. Pre-clinical and clinical studies have shown that AsiDNA, a double-stranded (DS) DNA molecule that mimics DS DNA breaks to interfere with DNA repair by over-activating a false DNA damage signaling through DNA-PK and PARP enzymes (decoy agonist), is extremely well tolerated in standalone in mammals. These observations led us to assess the potential of AsiDNA to protect healthy cells from toxicities of several anti-cancer treatments. Experimental design: In vivo, we analyzed the safety profile of AsiDNA during a recent clinical trial (DRIIV-1b/NCT03579628) in combination with platinum-based chemotherapy. In vitro, we used isolated blood cells from healthy donors, and epithelial and fibroblast cells as models to study if AsiDNA could protect healthy cells to chemo- and radiotherapy-induced toxicity. We monitored cell survival, DNA damage (comet assays) and repair (53BP1 and Rad51 foci), DNA-PK (HSP90 and H2AX phosphorylation) and PARP (PARylation) activation, cell cycle modulation and p53 dependency to identify mechanisms underlying the effects of AsiDNA on healthy cells. Results: In vivo, long-term treatment of several patients with carboplatine+/-paclitaxel + AsiDNA showed no increase of chemotherapies toxicities allowing longer periods of disease control and suggesting a protective effect of AsiDNA. In the in vitro models, we showed that AsiDNA enters non dividing and dividing healthy cells as revealed by intracellular PARylation but induces its nuclear target engagement (H2AX and HSP90 phosphorylation) only in dividing cells. Association of AsiDNA to antitumor treatments increased survival of healthy proliferative cells. Interestingly, AsiDNA displayed two distinct mechanisms of protection depending on the origin of the cells: p53-dependent G1/S cell cycle arrest in fibroblasts and epithelial cells, and DNA repair “doping” in hematological cells revealed by higher recruitment of Rad51 and 53BP1 at damage sites in those cells. Enzymatic inhibition and gene editing revealed that hyperactivation of DNA-PK/p53 pathway by AsiDNA might be required for healthy cells preservation. Conclusion: These findings suggest that the combination of AsiDNA with anticancer treatments should provide a means to attenuate therapy-induced toxicity, while showing the well-documented synergy in tumor cells, thus providing an opportunity to increase the therapeutic window. Citation Format: Wael Jdey, Anouk Sesink, Agathe Cohendet, Juliette Rieu, Chloe Doizelet, Vincent Hayes, Pierre-Marie Girard, Marie Dutreix, Judith Greciet. AsiDNA® treatment protects healthy cells from anticancer treatment toxicity [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr 2600.
- Published
- 2022
8. Anticancer effects of PARP1 hyperactivation by a decoy oligodeoxynucleotide in vitro and in vivo
- Author
-
Wael Jdey, Chloe Doizelet, Claudia Galassi, Christelle Zandanel, Veronique Trochon-Joseph, Vincent Hayes, Marie-Christine Lienafa, Giulia Petroni, and Lorenzo Galluzzi
- Subjects
Cancer Research ,Oncology - Abstract
e15060 Background: Poly (ADP-ribose) polymerase (PARP) inhibitors mediate significant anticancer effects against homologous recombination defective (HRD) tumors but have limited efficacy against homologous recombination proficient (HRP) neoplasms. Moreover, HRD tumors often become resistant to PARP inhibitors during treatment, constituting a major limitation to the clinical use of these agents. Here, we describe the metabolic, antineoplastic and immunomodulatory effects of a first-in-class oligodeoxynucleotide that operates as a PARP1 decoy (OX413), resulting in constitutive hyperactivation of PARP1 and consequent exhaustion of the DNA damage response. Methods: OX413-induced PARP trapping and hyperactivation, NAD+ consumption and cell cytotoxicity were monitored using (HRP and HRD) breast, ovarian or prostate cancer cells as well as normal fibroblasts and leukocytes. DNA repair abrogation was monitored by analyzing repair protein recruitment to damage sites. Accumulation of cytoplasmic DNA fragments was monitored after DNA staining and microscopy analysis. Effects on the innate immune response was assessed by following STING pathway activation and T-cell mediated anti-tumor cytotoxicity. In a mouse xenograft model of breast cancer, OX413-induced PARP activation and tumor infiltration by immune cells were analyzed ex-vivo by flow cytometry. Antitumor efficacy of OX413 alone or combined to a PD1 blocker was assessed in MPA/DMBA-driven HR+ HER2- mouse mammary carcinomas. Results: At odds with conventional PARP inhibitors, OX413 bound to and hyperactivated PARP1 with high affinity and in a dose-dependent manner, resulting in elevated cytotoxicity in multiple cancer (but not normal) cells irrespective of HR status. OX413 impaired DNA repair due to PARP trapping and rapid NAD+ consumption, leading to the accumulation of cytoplasmic chromatin fragments (CCFs). Consistent with this, OX413 triggered activation of the CGAS/STING pathway, CCL5 secretion and potentiation of tumor-targeting T cell responses. PARP1 engagement and STING activation were corroborated in vivo in EMT6 mouse mammary carcinomas, correlating with anticancer effects coupled to tumor infiltration by innate and adaptive immune cells. In MPA/DMBA-driven tumors, OX413 mediated considerable anticancer effects that could be exacerbated by PD1 inhibition. Conclusions: Our results provide preclinical rationale for using OX413 to trigger metabolic exhaustion in cancer cells and initiate inflammatory responses that can be actioned by immune checkpoint inhibitors in patients bearing HRD as well as HRP tumors.
- Published
- 2022
9. Dynamic intercellular redistribution of HIT antigen modulates heparin-induced thrombocytopenia
- Author
-
Mortimer Poncz, Daria Madeeva, Valerie Tutwiler, Jing Dai, Douglas B. Cines, Vincent Hayes, Hyun Sook Ahn, Gowthami M. Arepally, and Lubica Rauova
- Subjects
Blood Platelets ,0301 basic medicine ,Immunology ,Monocytopenia ,030204 cardiovascular system & hematology ,Platelet Factor 4 ,Biochemistry ,Monocytes ,Mice ,03 medical and health sciences ,0302 clinical medicine ,Heparin-induced thrombocytopenia ,Human Umbilical Vein Endothelial Cells ,medicine ,Animals ,Humans ,Platelet ,Antigens ,Whole blood ,Heparin ,Chemistry ,Monocyte ,Cell Biology ,Hematology ,medicine.disease ,Thrombocytopenia ,Molecular biology ,Endothelial stem cell ,030104 developmental biology ,medicine.anatomical_structure ,Gene Expression Regulation ,Platelet factor 4 ,medicine.drug - Abstract
Heparin-induced thrombocytopenia (HIT) is a prothrombotic disorder initiated by antibodies to platelet factor 4 (PF4)/heparin complexes. PF4 released from platelets binds to surface glycosaminoglycans on hematopoietic and vascular cells that are heterogenous in composition and differ in affinity for PF4. PF4 binds to monocytes with higher affinity than to platelets, and depletion of monocytes exacerbates thrombocytopenia in a murine HIT model. Here we show that the expression of PF4 on platelets and development of thrombocytopenia are modulated by the (re)distribution of PF4 among hematopoietic and endothelial cell surfaces. Binding of PF4 to platelets in whole blood in vitro varies inversely with the white cell count, likely because of the greater affinity of monocytes for PF4. In mice, monocyte depletion increased binding of PF4 to platelets by two- to three-fold. Induction of HIT in mice caused a transient >80-fold increase in binding of HIT antibody to monocytes vs 3.5-fold increase to platelets and rapid transient monocytopenia. Normalization of monocyte counts preceded the return in platelet counts. Exposure of blood to endothelial cells also depletes PF4 from platelet surfaces. These studies demonstrate a dynamic interchange of surface-bound PF4 among hematopoetic and vascular cells that may limit thrombocytopenia at the expense of promoting prothrombotic processes in HIT.
- Published
- 2018
10. Enhancing functional platelet release in vivo from in vitro–grown megakaryocytes using small molecule inhibitors
- Author
-
Randolph B. Lyde, Vincent Hayes, Mortimer Poncz, Danuta Jarocha, Rodney M. Camire, and Karen K. Vo
- Subjects
Blood Platelets ,0301 basic medicine ,Hematopoiesis and Stem Cells ,CD34 ,030204 cardiovascular system & hematology ,Pharmacology ,Thrombopoiesis ,Mice ,03 medical and health sciences ,chemistry.chemical_compound ,0302 clinical medicine ,Megakaryocyte ,medicine ,Animals ,Humans ,Platelet ,Protein Kinase Inhibitors ,Hematology ,Hematopoietic Stem Cells ,Immunohistochemistry ,Haematopoiesis ,030104 developmental biology ,Platelet transfusion ,medicine.anatomical_structure ,SU6656 ,chemistry ,Platelet aggregation inhibitor ,Megakaryocytes ,Biomarkers ,Platelet Aggregation Inhibitors - Abstract
In vitro-grown megakaryocytes for generating platelets may have value in meeting the increasing demand for platelet transfusions. Remaining challenges have included the poor yield and quality of in vitro-generated platelets. We have shown that infusing megakaryocytes leads to intrapulmonary release of functional platelets. A Src kinase inhibitor (SU6656), a Rho-associated kinase inhibitor (Y27632), and an aurora B kinase inhibitor (AZD1152) have been shown to increase megakaryocyte ploidy and in vitro proplatelet release. We now tested whether megakaryocytes generated from CD34+ hematopoietic cells in the presence of these inhibitors could enhance functional platelet yield following megakaryocyte infusion. As expected, all inhibitors increased megakaryocyte ploidy, size, and granularity, but these inhibitors differed in whether they injured terminal megakaryocytes: SU6656 was protective, whereas Y27632 and AZD1152 increased injury. Upon infusion, inhibitor-treated megakaryocytes released threefold to ninefold more platelets per initial noninjured megakaryocyte relative to control, but only SU6656-treated megakaryocytes had a significant increase in platelet yield when calculated based on the number of initial CD34+ cells; this was fourfold over nontreated megakaryocytes. The released platelets from drug-treated, but healthy, megakaryocytes contained similar percentages of young, uninjured platelets that robustly responded to agonists and were well incorporated into a growing thrombus in vivo as controls. These studies suggest that drug screens that select megakaryocytes with enhanced ploidy, cell size, and granularity may include a subset of drugs that can enhance the yield and function of platelets, and may have clinical application for ex vivo-generated megakaryocytes and platelet transfusion.
- Published
- 2018
11. Abstract 527: A new generation of PARP interfering drug candidates for cancer treatment
- Author
-
Wael Jdey, Vincent Hayes, Christelle Zandanel, Véronique Trochon-Joseph, Chloé Doizelet, Françoise Bono, Richard Tripelon, and Marie-Christine Lienafa
- Subjects
Drug ,Cancer Research ,Oncology ,business.industry ,media_common.quotation_subject ,Poly ADP ribose polymerase ,Cancer research ,Medicine ,business ,media_common ,Cancer treatment - Abstract
Purpose: Therapeutic strategies targeting DNA repair defects have been widely explored, but often restricted to a specific population of patients and tackled with resistance issues. We pioneered a new approach of anti-cancer treatment to tackle emergence of resistance: the decoy agonist mechanism of action. Drugs based on this mechanism hijack and hyperactivate therapeutic targets leading to an impairment of the repair signaling. This breakthrough decoy agonist action has already shown, using our lead compound AsiDNA™, target engagement, excellent safety profile in humans, and importantly lack of acquired resistance. Here, we describe mechanistically the immunomodulatory properties and metabolic effects of a new generation product OX401, generated using the proprietary PlatON™ platform of oligonucleotides designed to trap PARP proteins. Experimental design: OX401-induced PARP activation, NAD+ consumption and cell cytotoxicity were monitored using tumor and non-tumor cells. DNA repair abrogation was monitored by analyzing repair protein recruitment to damage sites. Accumulation of cytoplasmic DNA fragments was monitored after DNA staining and microscopy analysis. OX401 effect on the innate immune response was assessed by following STING pathway activation and T-cell mediated anti-tumor cytotoxicity. OX413, a “super” OX401 was designed to be more stable and less prone to intracellular enzymatic degradation. In a cell-derived xenograft model of mouse breast cancer, OX413-induced PARP activation and percentages of tumor-infiltrating leucocytes (CD45+: CD3+, CD8+, NK, DCs) were analyzed ex-vivo by flow cytometry. Results: Using different tumor models, we showed that OX401 binds and hyper-activates PARP1 with a high affinity and in a dose-dependent manner. As a consequence, OX401 impaired DNA repair due to PARP sequestration leading to an accumulation of cytoplasmic chromatin fragments (CCFs). In line with this, we demonstrated that OX401 displayed cell-autonomous immunomodulatory properties. Mechanistically, the generated CCFs triggered an innate immunity activation through cGAS/STING pathway, downstream CCL5 secretion and potentiation of the anti-tumor T-cell dependent immune response. Through PARP hyper-activation, OX401 also induced a rapid NAD+ consumption (below the viability threshold). This metabolic exhaustion caused selective tumor cell death while sparing healthy cells. These effects were enhanced using the optimized OX413 molecule, and at doses approximately 10 to 100-fold lower compared to OX401. In-vivo, OX413 triggered PARP1 target engagement and STING pathway activation, correlated to an increased innate and adaptive immune cells infiltration. Conclusions: Our results provide a preclinical rationale for using OX413 as an immunomodulatory and “metabolic exhauster” agent, especially in appropriately molecularly selected patients with tumors showing metabolic deficiencies. Citation Format: Wael Jdey, Christelle Zandanel, Véronique Trochon-Joseph, Chloé Doizelet, Vincent Hayes, Marie-Christine Lienafa, Richard Tripelon, Françoise Bono. A new generation of PARP interfering drug candidates for cancer treatment [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2021; 2021 Apr 10-15 and May 17-21. Philadelphia (PA): AACR; Cancer Res 2021;81(13_Suppl):Abstract nr 527.
- Published
- 2021
12. Identifying and enriching platelet-producing human stem cell–derived megakaryocytes using factor V uptake
- Author
-
Rodney M. Camire, Deborah L. French, Danuta Jarocha, Mortimer Poncz, Hayley A. Hanby, Michael S. Marks, Vincent Hayes, Xiuli Sim, and Paul Gadue
- Subjects
Blood Platelets ,0301 basic medicine ,Cellular differentiation ,Immunology ,Gene Expression ,Apoptosis ,Bone Marrow Cells ,Mice, SCID ,030204 cardiovascular system & hematology ,Biochemistry ,Immunophenotyping ,Flow cytometry ,Mice ,03 medical and health sciences ,0302 clinical medicine ,In vivo ,medicine ,Animals ,Humans ,Cell Lineage ,Platelet ,Megakaryocyte Progenitor Cells ,biology ,medicine.diagnostic_test ,Lasers ,Factor V ,Cell Differentiation ,Platelet Glycoprotein GPIb-IX Complex ,Cell Biology ,Hematology ,Flow Cytometry ,Molecular biology ,Endocytosis ,In vitro ,Arterioles ,030104 developmental biology ,Glycoprotein Ib ,biology.protein ,Stem cell ,Megakaryocytes ,Biomarkers - Abstract
Stem cell-derived platelets have the potential to replace donor platelets for transfusion. Defining the platelet-producing megakaryocytes (MKs) within the heterogeneous MK culture may help to optimize the in vitro generation of platelets. Using 2 human stem cell models of megakaryopoiesis, we identified novel MK populations corresponding to distinct maturation stages. An immature, low granular (LG) MK pool (defined by side scatter on flow cytometry) gives rise to a mature high granular (HG) pool, which then becomes damaged by apoptosis and glycoprotein Ib α chain (CD42b) shedding. We define an undamaged HG/CD42b+ MK subpopulation, which endocytoses fluorescently labeled coagulation factor V (FV) from the media into α-granules and releases functional FV+CD42b+ human platelet-like particles in vitro and when infused into immunodeficient mice. Importantly, these FV+ particles have the same size distribution as infused human donor platelets and are preferentially incorporated into clots after laser injury. Using drugs to protect HG MKs from apoptosis and CD42b shedding, we also demonstrate that apoptosis precedes CD42b shedding and that apoptosis inhibition enriches the FV+ HG/CD42b+ MKs, leading to increased platelet yield in vivo, but not in vitro. These studies identify a transition between distinct MK populations in vitro, including one that is primed for platelet release. Technologies to optimize and select these platelet-ready MKs may be important to efficiently generate functional platelets from in vitro-grown MKs.
- Published
- 2017
13. FLI1 level during megakaryopoiesis affects thrombopoiesis and platelet biology
- Author
-
Christopher S. Thom, Vincent Hayes, Danuta Jarocha, Mortimer Poncz, Deborah L. French, Karen K. Vo, Randolph B. Lyde, and Spencer K. Sullivan
- Subjects
0301 basic medicine ,Megakaryocyte differentiation ,Cellular differentiation ,Immunology ,Biology ,Biochemistry ,03 medical and health sciences ,0302 clinical medicine ,Megakaryocyte ,medicine ,Humans ,Platelet ,Jacobsen Distal 11q Deletion Syndrome ,Thrombopoiesis ,Megakaryopoiesis ,Megakaryocytopoiesis ,Proto-Oncogene Protein c-fli-1 ,Chromosomes, Human, Pair 11 ,fungi ,Cell Biology ,Hematology ,Platelets and Thrombopoiesis ,030104 developmental biology ,medicine.anatomical_structure ,030220 oncology & carcinogenesis ,FLI1 ,Cancer research - Abstract
Friend leukemia virus integration 1 (FLI1), a critical transcription factor (TF) during megakaryocyte differentiation, is among genes hemizygously deleted in Jacobsen syndrome, resulting in a macrothrombocytopenia termed Paris-Trousseau syndrome (PTSx). Recently, heterozygote human FLI1 mutations have been ascribed to cause thrombocytopenia. We studied induced-pluripotent stem cell (iPSC)-derived megakaryocytes (iMegs) to better understand these clinical disorders, beginning with iPSCs generated from a patient with PTSx and iPSCs from a control line with a targeted heterozygous FLI1 knockout (FLI1+/-). PTSx and FLI1+/- iMegs replicate many of the described megakaryocyte/platelet features, including a decrease in iMeg yield and fewer platelets released per iMeg. Platelets released in vivo from infusion of these iMegs had poor half-lives and functionality. We noted that the closely linked E26 transformation-specific proto-oncogene 1 (ETS1) is overexpressed in these FLI1-deficient iMegs, suggesting FLI1 negatively regulates ETS1 in megakaryopoiesis. Finally, we examined whether FLI1 overexpression would affect megakaryopoiesis and thrombopoiesis. We found increased yield of noninjured, in vitro iMeg yield and increased in vivo yield, half-life, and functionality of released platelets. These studies confirm FLI1 heterozygosity results in pleiotropic defects similar to those noted with other critical megakaryocyte-specific TFs; however, unlike those TFs, FLI1 overexpression improved yield and functionality.
- Published
- 2017
14. Endothelial antigen assembly leads to thrombotic complications in heparin-induced thrombocytopenia
- Author
-
Douglas B. Cines, Lubica Rauova, Ian Johnston, Vincent Hayes, Mortimer Poncz, Gowthami M. Arepally, and Steven E. McKenzie
- Subjects
Blood Platelets ,Male ,0301 basic medicine ,Endothelium ,030204 cardiovascular system & hematology ,Glycocalyx ,Platelet Factor 4 ,Fibrin ,03 medical and health sciences ,0302 clinical medicine ,Antigen ,Heparin-induced thrombocytopenia ,medicine ,Animals ,Humans ,Platelet ,Thrombus ,Mice, Knockout ,biology ,Heparin ,Chemistry ,Receptors, IgG ,Thrombosis ,General Medicine ,medicine.disease ,Thrombocytopenia ,Disease Models, Animal ,030104 developmental biology ,medicine.anatomical_structure ,biology.protein ,Cancer research ,Female ,Platelet factor 4 ,Research Article ,medicine.drug - Abstract
Heparin-induced thrombocytopenia (HIT) is a prothrombotic disorder initiated by antibodies against complexes between human platelet factor 4 (hPF4) and heparin. A better understanding of the events that initiate the prothrombotic state may improve approaches to antithrombotic management. Here, we visualized thrombus formation in an in vivo murine model and an endothelialized microfluidic system that simulate the pathogenesis of HIT. hPF4 released from platelets predominantly bound to peri-injury endothelium and formed HIT antigenic complexes that were dissociated by heparin. In mice expressing both hPF4+ and human platelet IgG Fc receptor IIA (FcγRIIA), infusion of the HIT-like monoclonal antibody KKO increased fibrin and platelet deposition at sites of injury, followed immediately by antigen formation on proximate endothelial cells. After a few minutes, HIT antigen was detected within the thrombus itself at the interface between the platelet core and the surrounding shell. We observed similar results in the humanized, endothelialized microfluidic system. hPF4 and KKO selectively bound to photochemically injured endothelium at sites where surface glycocalyx was reduced. These studies support the concept that the perithrombus endothelium is the predominant site of HIT antigen assembly. This suggests that disrupting antigen formation along the endothelium or protecting the endothelium may provide a therapeutic opportunity to prevent thrombotic complications of HIT, while sparing systemic hemostatic pathways.
- Published
- 2017
15. Structure-guided design of a pure orthosteric antagonist of integrin αlIbβ3 that inhibits thrombosis but not clot retraction
- Author
-
Hyun Sook Ahn, M. Amin Arnaout, Shu-Wha Lin, José Luis Alonso, Vincent Hayes, Jian-Ping Xiong, Brian D. Adair, Johannes van Agthoven, I-Shing Yu, and Mortimer Poncz
- Subjects
0303 health sciences ,business.industry ,Tirofiban ,Clot retraction ,030204 cardiovascular system & hematology ,medicine.disease ,Bioinformatics ,Thrombosis ,Partial agonist ,3. Good health ,03 medical and health sciences ,0302 clinical medicine ,Hemostasis ,Humanized mouse ,Eptifibatide ,medicine ,Platelet ,business ,030304 developmental biology ,medicine.drug - Abstract
A prevailing dogma is that effective inhibition of vascular thrombosis by therapeutic targeting of platelet integrin αIIbβ3 cannot be achieved without compromising hemostasis. The resulting serious bleeding and increased morbidity and mortality have limited use of current anti-αIIbβ3 drugs to high-risk cardiac patients. It is speculated that these adverse outcomes result from drug-induced conformational changes in αIIbβ3 but direct proof is lacking. We used structure-guided design to generate the ligand-mimetic peptide Hr10 and a modified form of the partial agonist drug Tirofiban that now act as “pure” orthosteric antagonists of αIIbβ3, i.e. they no longer induce the conformational changes in αIIbβ3 and also suppress these changes in presence of agonists. Both agents inhibited human platelet aggregation effectively but without interfering with clot retraction. When tested in a humanized mouse model of thrombosis predictive of clinical efficacy, Hr10 was as effective as the αIIbβ3 partial agonist peptide drug Eptifibatide in inhibiting arteriolar thrombosis, but in sharp contrast to Eptifibatide, Hr10 did not cause serious bleeding, establishing a causal link between partial agonism and impaired hemostasis. Pure orthosteric inhibitors of αIIbβ3 may thus offer safer alternatives for human therapy. Our structure-guided approach may also find utility in designing similar drug candidates targeting other integrins and in providing vital tools for further probing structure-activity relationships in integrins.
- Published
- 2018
- Full Text
- View/download PDF
16. ADAMTS13 autoantibodies cloned from patients with acquired thrombotic thrombocytopenic purpura: 2. Pathogenicity in an animal model
- Author
-
X. Long Zheng, Michelle Thiboutot, Douglas B. Cines, Mortimer Poncz, Khalil Bdeir, David G. Motto, Lenka Yunk, Stephen Kacir, Eric M. Ostertag, Vincent Hayes, Don L. Siegel, and Gayathri Gulendran
- Subjects
0301 basic medicine ,Acquired Thrombotic Thrombocytopenic Purpura ,biology ,business.industry ,Immunology ,Autoantibody ,Hematology ,030204 cardiovascular system & hematology ,ADAMTS13 ,Immunoglobulin G ,03 medical and health sciences ,030104 developmental biology ,0302 clinical medicine ,Von Willebrand factor ,Naked DNA ,In vivo ,hemic and lymphatic diseases ,biology.protein ,Immunology and Allergy ,Medicine ,Platelet ,business - Abstract
BACKGROUND Acquired thrombotic thrombocytopenic purpura (TTP) is a potentially fatal disease in which ultralarge von Willebrand factor (UL-VWF) multimers accumulate as a result of autoantibody inhibition of the VWF protease, ADAMTS13. Current treatment is not specifically directed at the responsible autoantibodies and in some cases is ineffective or of transient benefit. More rational, reliable, and durable therapies are needed, and a human autoantibody-mediated animal model would be useful for their development. Previously, TTP patient anti-ADAMTS13 single-chain variable-region fragments (scFv's) were cloned that inhibited ADAMTS13 proteolytic activity in vitro and expressed features in common with inhibitory immunoglobulin G in patient plasma. Here, pathogenicity of these scFv's is explored in vivo by transfecting mice with inhibitory antibody cDNA. STUDY DESIGN AND METHODS Hydrodynamic tail vein injection of naked DNA encoding human anti-ADAMTS13 scFv was used to create sustained ADAMTS13 inhibition in mice. Accumulation of UL-VWF multimers was measured and formation of platelet (PLT) thrombi after focal or systemic vascular injury was examined. RESULTS Transfected mice expressed physiological plasma levels of human scFv and developed sustained ADAMTS13 inhibition and accumulation of unprocessed UL-VWF multimers. Induced focal endothelial injury generated PLT thrombi extending well beyond the site of initial injury, and systemic endothelial injury induced thrombocytopenia, schistocyte formation, PLT thrombi, and death. CONCLUSIONS These results demonstrate for the first time the ability of human recombinant monovalent anti-ADAMTS13 antibody fragments to recapitulate key pathologic features of untreated acquired TTP in vivo, validating their clinical significance and providing an animal model for testing novel targeted therapeutic approaches.
- Published
- 2016
17. Platelet transactivation by monocytes promotes thrombosis in heparin-induced thrombocytopenia
- Author
-
Valerie Tutwiler, Douglas B. Cines, Mortimer Poncz, Lubica Rauova, X. Long Zheng, Izabella A. Andrianova, Steven E. McKenzie, Hyun Sook Ahn, Daria Madeeva, and Vincent Hayes
- Subjects
Blood Platelets ,0301 basic medicine ,Immunology ,030204 cardiovascular system & hematology ,Platelet Factor 4 ,Biochemistry ,Monocytes ,Mice ,03 medical and health sciences ,Tissue factor ,0302 clinical medicine ,Thrombin ,Heparin-induced thrombocytopenia ,Animals ,Humans ,Medicine ,Platelet ,Platelet activation ,Cells, Cultured ,Heparin ,business.industry ,Monocyte ,Receptors, IgG ,Anticoagulants ,Thrombosis ,Cell Biology ,Hematology ,Microfluidic Analytical Techniques ,Platelets and Thrombopoiesis ,Platelet Activation ,medicine.disease ,Thrombocytopenia ,030104 developmental biology ,medicine.anatomical_structure ,Cancer research ,business ,Platelet factor 4 ,medicine.drug - Abstract
Heparin-induced thrombocytopenia (HIT) is characterized by a high incidence of thrombosis, unlike other antibody-mediated causes of thrombocytopenia. We have shown that monocytes complexed with surface-bound platelet factor 4 (PF4) activated by HIT antibodies contribute to the prothrombotic state in vivo, but the mechanism by which this occurs and the relationship to the requirement for platelet activation via fragment crystallizable (Fc)γRIIA is uncertain. Using a microfluidic model and human or murine blood, we confirmed that activation of monocytes contributes to the prothrombotic state in HIT and showed that HIT antibodies bind to monocyte FcγRIIA, which activates spleen tyrosine kinase and leads to the generation of tissue factor (TF) and thrombin. The combination of direct platelet activation by HIT immune complexes through FcγRIIA and transactivation by monocyte-derived thrombin markedly increases Annexin V and factor Xa binding to platelets, consistent with the formation of procoagulant coated platelets. These data provide a model of HIT wherein a combination of direct FcγRIIA-mediated platelet activation and monocyte-derived thrombin contributes to thrombosis in HIT and identifies potential new targets for lessening this risk.
- Published
- 2016
18. A chimeric platelet-targeted urokinase prodrug selectively blocks new thrombus formation
- Author
-
Victoria Stepanova, Mortimer Poncz, M. Anna Kowalska, Michele P. Lambert, Don L. Siegel, Daniel D. Myers, Vincent Hayes, Daniel W. Bougie, Sergei Zaitsev, Richard H. Aster, Hyun Sook Ahn, Vladimir R. Muzykantov, Douglas B. Cines, Yuhuan Wang, and Rudy Fuentes
- Subjects
Blood Platelets ,Recombinant Fusion Proteins ,medicine.medical_treatment ,Mice, SCID ,030204 cardiovascular system & hematology ,Mice ,03 medical and health sciences ,Drug Delivery Systems ,0302 clinical medicine ,Thrombin ,Mice, Inbred NOD ,Fibrinolysis ,medicine ,Animals ,Humans ,Prodrugs ,Platelet ,Platelet activation ,Thrombus ,030304 developmental biology ,Mice, Knockout ,Urokinase ,0303 health sciences ,Chemistry ,Thrombosis ,General Medicine ,Prodrug ,medicine.disease ,Urokinase-Type Plasminogen Activator ,3. Good health ,Immunology ,Cancer research ,Fibrinolytic agent ,Research Article ,medicine.drug - Abstract
The use of fibrinolytic agents to prevent new thrombus formation is limited by an increased risk of bleeding due to lysis of hemostatic clots that prevent hemorrhage in damaged blood vessels. We sought to develop an agent that provides thromboprophylaxis without carrying a significant risk of causing systemic fibrinolysis or disrupting hemostatic clots. We previously showed that platelet (PLT) α granule-delivered urokinase plasminogen activator (uPA) is highly effective in preventing thrombosis, while being associated with little systemic fibrinolysis or bleeding. Here, we generated a chimeric prodrug composed of a single-chain version of the variable region of an anti-αIIbβ3 mAb fused to a thrombin-activatable, low-molecular-weight pro-uPA (PLT/uPA-T). PLT/uPA-T recognizes human αIIbβ3 on both quiescent and activated platelets and is enzymatically activated specifically by thrombin. We found that this prodrug binds tightly to human platelets even after gel filtration, has a prolonged half-life in mice transgenic for human αIIb compared with that of uPA-T, and prevents clot formation in a microfluidic system. Importantly, in two murine injury models, PLT/uPA-T did not lyse preexisting clots, even when administration was delayed by as little as 10 minutes, while it concurrently prevented the development of nascent thrombi. Thus, PLT/uPA-T represents the prototype of a platelet-targeted thromboprophylactic agent that selectively targets nascent over preexisting thrombi.
- Published
- 2015
19. The C-terminal CGHC motif of protein disulfide isomerase supports thrombosis
- Author
-
Mortimer Poncz, Lu Wang, David W. Essex, Junsong Zhou, Yi Wu, Lubica Rauova, and Vincent Hayes
- Subjects
Blood Platelets ,inorganic chemicals ,Platelet Aggregation ,P-selectin ,Amino Acid Motifs ,Protein Disulfide-Isomerases ,Mice, Transgenic ,Fibrin ,law.invention ,Mice ,Chlorides ,law ,Animals ,Humans ,Platelet ,Secretion ,Platelet activation ,Protein disulfide-isomerase ,Blood Coagulation ,biology ,Chemistry ,Thrombosis ,General Medicine ,Molecular biology ,In vitro ,Protein Structure, Tertiary ,nervous system diseases ,3. Good health ,body regions ,P-Selectin ,Biochemistry ,biology.protein ,Recombinant DNA ,Iron Compounds ,Research Article - Abstract
Protein disulfide isomerase (PDI) has two distinct CGHC redox-active sites; however, the contribution of these sites during different physiologic reactions, including thrombosis, is unknown. Here, we evaluated the role of PDI and redox-active sites of PDI in thrombosis by generating mice with blood cells and vessel wall cells lacking PDI (Mx1-Cre Pdifl/fl mice) and transgenic mice harboring PDI that lacks a functional C-terminal CGHC motif [PDI(ss-oo) mice]. Both mouse models showed decreased fibrin deposition and platelet accumulation in laser-induced cremaster arteriole injury, and PDI(ss-oo) mice had attenuated platelet accumulation in FeCl3-induced mesenteric arterial injury. These defects were rescued by infusion of recombinant PDI containing only a functional C-terminal CGHC motif [PDI(oo-ss)]. PDI infusion restored fibrin formation, but not platelet accumulation, in eptifibatide-treated wild-type mice, suggesting a direct role of PDI in coagulation. In vitro aggregation of platelets from PDI(ss-oo) mice and PDI-null platelets was reduced; however, this defect was rescued by recombinant PDI(oo-ss). In human platelets, recombinant PDI(ss-oo) inhibited aggregation, while recombinant PDI(oo-ss) potentiated aggregation. Platelet secretion assays demonstrated that the C-terminal CGHC motif of PDI is important for P-selectin expression and ATP secretion through a non-αIIbβ3 substrate. In summary, our results indicate that the C-terminal CGHC motif of PDI is important for platelet function and coagulation.
- Published
- 2015
20. Recognition of PF4-VWF complexes by heparin-induced thrombocytopenia antibodies contributes to thrombus propagation
- Author
-
Mortimer Poncz, Douglas B. Cines, Junmei Chen, Lubica Rauova, Vincent Hayes, Amrita Sarkar, Ian Johnston, Gowthami M. Arepally, Dominic W. Chung, Gavin T. Koma, and José A. López
- Subjects
medicine.drug_class ,Immunology ,Monoclonal antibody ,Platelet Factor 4 ,Biochemistry ,Antibodies ,Thrombosis and Hemostasis ,Mice ,Platelet Adhesiveness ,Von Willebrand factor ,hemic and lymphatic diseases ,Heparin-induced thrombocytopenia ,von Willebrand Factor ,medicine ,Human Umbilical Vein Endothelial Cells ,Animals ,Humans ,Platelet ,Thrombus ,biology ,Chemistry ,Heparin ,Anticoagulants ,Thrombosis ,Cell Biology ,Hematology ,medicine.disease ,Thrombocytopenia ,Mice, Inbred C57BL ,cardiovascular system ,Cancer research ,biology.protein ,Antibody ,Platelet factor 4 ,circulatory and respiratory physiology ,medicine.drug - Abstract
Heparin-induced thrombocytopenia (HIT) is a prothrombotic disorder mediated by complexes between platelet factor 4 (PF4) and heparin or other polyanions, but the risk of thrombosis extends beyond exposure to heparin implicating other PF4 partners. We recently reported that peri-thrombus endothelium is targeted by HIT antibodies, but the binding site(s) has not been identified. We now show that PF4 binds at multiple discrete sites along the surface of extended strings of von Willebrand factor (VWF) released from the endothelium following photochemical injury in an endothelialized microfluidic system under flow. The HIT-like monoclonal antibody KKO and HIT patient antibodies recognize PF4-VWF complexes, promoting platelet adhesion and enlargement of thrombi within the microfluidic channels. Platelet adhesion to the PF4-VWF-HIT antibody complexes is inhibited by antibodies that block FcγRIIA or the glycoprotein Ib-IX complex on platelets. Disruption of PF4-VWF-HIT antibody complexes by drugs that prevent or block VWF oligomerization attenuate thrombus formation in a murine model of HIT. Together, these studies demonstrate assembly of HIT immune complexes along VWF strings released by injured endothelium that might propagate the risk of thrombosis in HIT. Disruption of PF4-VWF complex formation may provide a new therapeutic approach to HIT.
- Published
- 2018
21. Neutrophil accumulation and NET release contribute to thrombosis in HIT
- Author
-
Mortimer Poncz, Adam Cuker, Michele P. Lambert, Lubica Rauova, Minna Kim, Kandace Gollomp, Mark L. Kahn, Douglas B. Cines, Gowthami M. Arepally, M. Anna Kowalska, Ian Johnston, Vincent Hayes, and John Welsh
- Subjects
0301 basic medicine ,Male ,medicine.medical_specialty ,Neutrophils ,Inflammation ,Platelet Factor 4 ,Extracellular Traps ,Neutrophil Activation ,Receptors, Interleukin-8B ,Autoimmune Diseases ,03 medical and health sciences ,Mice ,Protein-Arginine Deiminase Type 4 ,Cell Movement ,Internal medicine ,medicine ,Leukocytes ,Animals ,Humans ,Thrombus ,Lymphatic Vessels ,Mice, Knockout ,Hematology ,biology ,business.industry ,Endothelial Cells ,Thrombosis ,General Medicine ,Neutrophil extracellular traps ,medicine.disease ,Thrombocytopenia ,Venous thrombosis ,030104 developmental biology ,Cancer research ,biology.protein ,Protein-Arginine Deiminases ,medicine.symptom ,Antibody ,business ,Infiltration (medical) ,Research Article - Abstract
Heparin-induced thrombocytopenia (HIT) is an immune-mediated thrombocytopenic disorder associated with a severe prothrombotic state. We investigated whether neutrophils and neutrophil extracellular traps (NETs) contribute to the development of thrombosis in HIT. Using an endothelialized microfluidic system and a murine passive immunization model, we show that HIT induction leads to increased neutrophil adherence to venous endothelium. In HIT mice, endothelial adherence is enhanced immediately downstream of nascent venous thrombi, after which neutrophils undergo retrograde migration via a CXCR2-dependent mechanism to accumulate into the thrombi. Using a microfluidic system, we found that PF4 binds to NETs, leading them to become compact and DNase resistant. PF4-NET complexes selectively bind HIT antibodies, which further protect them from nuclease digestion. In HIT mice, inhibition of NET formation through Padi4 gene disruption or DNase treatment limited venous thrombus size. PAD4 inactivation did affect arterial thrombi or severity of thrombocytopenia in HIT. Thus, neutrophil activation contributes to the development of venous thrombosis in HIT by enhancing neutrophil-endothelial adhesion and neutrophil clot infiltration, where incorporated PF4-NET-HIT antibody complexes lead to thrombosis propagation. Inhibition of neutrophil endothelial adhesion, prevention of neutrophil chemokine-dependent recruitment of neutrophils to thrombi, or suppression of NET release should be explored as strategies to prevent venous thrombosis in HIT.
- Published
- 2017
22. The disulfide isomerase ERp57 is required for fibrin deposition in vivo
- Author
-
Lu Wang, David W. Essex, Junsong Zhou, Lubica Rauova, Vincent Hayes, Yi Wu, and Mortimer Poncz
- Subjects
Blood Platelets ,Time Factors ,Isomerase activity ,Platelet Aggregation ,Protein Disulfide-Isomerases ,Article ,Fibrin ,Fibrinolytic Agents ,In vivo ,Animals ,Platelet ,Protein disulfide-isomerase ,Blood Coagulation ,Mice, Knockout ,biology ,Chemistry ,Antibodies, Monoclonal ,Endothelial Cells ,Thrombosis ,Hematology ,Molecular biology ,Disease Models, Animal ,Coagulation ,Biochemistry ,biology.protein ,Platelet aggregation inhibitor ,Laser Therapy ,Platelet Aggregation Inhibitors ,Fibrinolytic agent ,Signal Transduction - Abstract
Summary Background ERp57 is required for platelet function; however, whether ERp57 contributes to fibrin generation is unknown. Methods and Results Using an inhibitory anti-ERp57 antibody (mAb1), Pf4-Cre/ERp57fl/fl mice, Tie2-Cre/ERp57fl/fl mice, and mutants of ERp57, we analyzed the function of ERp57 in laser-induced thrombosis. Fibrin deposition was decreased in Pf4-Cre/ERp57fl/fl mice, consistent with a role for platelet ERp57 in fibrin generation. Fibrin deposition was further decreased with infusion of mAb1 and in Tie2-Cre/ERp57fl/fl mice, consistent with endothelial cells also contributing to fibrin deposition. Infusion of eptibifatide inhibited platelet and fibrin deposition, confirming a role for platelets in fibrin deposition. Infusion of recombinant ERp57 corrected the defect in fibrin deposition but not platelet accumulation, suggesting a direct effect of ERp57 on coagulation. mAb1 inhibited thrombin generation in vitro, consistent with a requirement for ERp57 in coagulation. Platelet accumulation was decreased to similar extents in Pf4-Cre/ERp57fl/fl mice, Tie2-Cre/ERp57fl/fl mice and normal mice infused with mAb1. Infusion of completely inactivated ERp57 or ERp57 with a non-functional second active site inhibited fibrin deposition and platelet accumulation, indicating that the isomerase activity of the second active site is required for these processes. Conclusion ERp57 regulates thrombosis via multiple targets.
- Published
- 2014
23. Threading an elephant through the eye of a needle: Where are platelets made?
- Author
-
Mortimer Poncz, Vincent Hayes, and Ian Johnston
- Subjects
0301 basic medicine ,Blood Platelets ,Male ,Pathology ,medicine.medical_specialty ,medicine.medical_treatment ,Hematopoietic stem cell transplantation ,Biology ,03 medical and health sciences ,Mice ,0302 clinical medicine ,Bone Marrow ,Platelet production ,Platelet release ,medicine ,Lung transplantation ,Animals ,Platelet ,Cell Lineage ,Molecular Biology ,Lung ,Platelet Count ,Microcirculation ,Cell Biology ,Anatomy ,respiratory system ,Hematopoietic Stem Cells ,Research Highlight ,Thrombocytopenia ,respiratory tract diseases ,Hematopoiesis ,Haematopoiesis ,030104 developmental biology ,030220 oncology & carcinogenesis ,Female ,Threading (protein sequence) ,Megakaryocytes - Abstract
Platelets are critical for haemostasis, thrombosis, and inflammatory responses, but the events that lead to mature platelet production remain incompletely understood. The bone marrow has been proposed to be a major site of platelet production, although there is indirect evidence that the lungs might also contribute to platelet biogenesis. Here, by directly imaging the lung microcirculation in mice, we show that a large number of megakaryocytes circulate through the lungs, where they dynamically release platelets. Megakaryocytes that release platelets in the lungs originate from extrapulmonary sites such as the bone marrow; we observed large megakaryocytes migrating out of the bone marrow space. The contribution of the lungs to platelet biogenesis is substantial, accounting for approximately 50% of total platelet production or 10 million platelets per hour. Furthermore, we identified populations of mature and immature megakaryocytes along with haematopoietic progenitors in the extravascular spaces of the lungs. Under conditions of thrombocytopenia and relative stem cell deficiency in the bone marrow, these progenitors can migrate out of the lungs, repopulate the bone marrow, completely reconstitute blood platelet counts, and contribute to multiple haematopoietic lineages. These results identify the lungs as a primary site of terminal platelet production and an organ with considerable haematopoietic potential.
- Published
- 2017
24. The disulfide isomerase ERp72 supports arterial thrombosis in mice
- Author
-
Yi Wu, Lu Wang, Junsong Zhou, Mortimer Poncz, Lubica Rauova, Junling Liu, Vincent Hayes, Tong Liu, David W. Essex, Hong Li, and Fengwu Chen
- Subjects
0301 basic medicine ,Blood Platelets ,P-selectin ,Immunology ,Platelet Glycoprotein GPIIb-IIIa Complex ,Biochemistry ,Fibrin ,Thrombosis and Hemostasis ,03 medical and health sciences ,chemistry.chemical_compound ,Mice ,Animals ,Humans ,Platelet ,Platelet activation ,Protein disulfide-isomerase ,Mice, Knockout ,Membrane Glycoproteins ,biology ,Chemistry ,Endoplasmic reticulum ,Thrombosis ,Cell Biology ,Hematology ,Platelet Activation ,Molecular biology ,030104 developmental biology ,Coagulation ,biology.protein ,Adenosine triphosphate - Abstract
Several CGHC motif-containing disulfide isomerases support thrombosis. We here report that endoplasmic reticulum protein 72 (ERp72), with 3 CGHC redox-active sites (ao, a, and a'), supports thrombosis. We generated a new conditional knockout mouse model and found that Tie2-Cre/ERp72fl/fl mice with blood and endothelial cells lacking ERp72 had prolonged tail bleeding times and decreased platelet accumulation in laser-induced cremaster arteriole injury and FeCl3-induced mesenteric arterial injury. Fibrin deposition was decreased in the laser injury model. Both platelet and fibrin accumulation defects were fully rescued by infusion of recombinant ERp72 containing functional a and a' CGHC motifs (ERp72(oo-ss-ss)). Infusion of ERp72 containing inactivated a and a' CGHC motifs (ERp72(ss-oo-oo)) inhibited platelet accumulation and fibrin deposition in wild-type mice. Infusion of ERp72(oo-ss-ss) into β3-null mice increased fibrin deposition in the absence of platelets. ERp72-null platelets had defective aggregation, JON/A binding, P-selectin expression, and adenosine triphosphate (ATP) secretion. The aggregation and ATP secretion defects were fully rescued by ERp72(oo-ss-ss) but partially rescued by ERp72(ss-oo-ss) and ERp72(ss-ss-oo). Aggregation and ATP secretion of human platelets was potentiated by ERp72(oo-ss-ss) but inhibited by ERp72(ss-oo-ss) and ERp72(ss-ss-oo). These data suggest that both the a and a' active sites are required for platelet function. ERp72 bound poorly to β3-null mouse platelets, and the addition of ERp72(oo-ss-ss) to human platelets generated thiols in αIIbβ3, suggesting a direct interaction of ERp72 with αIIbβ3. Defective aggregation of ERp72-null platelets was recovered by ERp72, but not other thiol isomerases. In summary, ERp72 plays a critical role in platelet function and coagulation through the a and a' CGHC motifs.
- Published
- 2016
25. Loss of ATE1-mediated arginylation leads to impaired platelet myosin phosphorylation, clot retraction, and in vivo thrombosis formation
- Author
-
Mortimer Poncz, Tao Xu, John R. Yates, Xuemei Han, Vincent Hayes, Lurong Lian, Anna Kashina, Aae Suzuki, Charles S. Abrams, and Sougata Saha
- Subjects
Blood Platelets ,Models, Molecular ,Myosin Light Chains ,Myosin light-chain kinase ,Protein Conformation ,Clot Retraction ,Gene Expression ,macromolecular substances ,Clot retraction ,Myosins ,Biology ,Mice ,Myosin ,Protein arginylation ,Animals ,Platelet activation ,Phosphorylation ,Cytoskeleton ,Actin ,Mice, Knockout ,Thrombosis ,Hematology ,Aminoacyltransferases ,Actin cytoskeleton ,Molecular biology ,Actins ,Cell biology ,Disease Models, Animal - Abstract
Protein arginylation by arginyl–transfer RNA protein transferase (ATE1) is emerging as a regulator protein function that is reminiscent of phosphorylation. For example, arginylation of β-actin has been found to regulate lamellipodial formation at the leading edge in fibroblasts. This finding suggests that similar functions of β-actin in other cell types may also require arginylation. Here, we have tested the hypothesis that ATE1 regulates the cytoskeletal dynamics essential for in vivo platelet adhesion and thrombus formation. To test this hypothesis, we generated conditional knockout mice specifically lacking ATE1 in their platelets and in their megakaryocytes and analyzed the role of arginylation during platelet activation. Surprisingly, rather than finding an impairment of the actin cytoskeleton structure and its rearrangement during platelet activation, we observed that the platelet-specific ATE1 knockout led to enhanced clot retraction and in vivo thrombus formation. This effect might be regulated by myosin II contractility since it was accompanied by enhanced phosphorylation of the myosin regulatory light chain on Ser19, which is an event that activates myosin in vivo. Furthermore, ATE1 and myosin co-immunoprecipitate from platelet lysates. This finding suggests that these proteins directly interact within platelets. These results provide the first evidence that arginylation is involved in phosphorylation-dependent protein regulation, and that arginylation affects myosin function in platelets during clot retraction.
- Published
- 2013
26. A Novel Anti-Glycoprotein (GP) Iba-Targeting Chimeric Fibrinolytic Agent Demonstrates In Vivo Efficacy Against Human Platelet-Enriched Thrombi in Mice
- Author
-
Hyunsook Ahn, Randolph B. Lyde, Mortimer Poncz, Zaverio M. Ruggeri, Shu-Wha Lin, Sergei Zaistev, Vincent Hayes, Renhao Li, Douglas B. Cines, and Vladimir R. Muzykantov
- Subjects
Urokinase ,biology ,Immunology ,Platelet Glycoprotein GPIb-IX Complex ,Cell Biology ,Hematology ,Pharmacology ,Biochemistry ,Thrombin ,Von Willebrand factor ,In vivo ,biology.protein ,medicine ,Platelet ,Receptor ,Fibrinolytic agent ,medicine.drug - Abstract
We previously described (Fuentes, J Clin Invest 2016) a chimeric protein, GPIIb/uPA-T, that provided effective thromboprophylaxis composed of an N-terminal scFv specifically to human (h) GPIIb linked to a C-terminal variant of low molecular weight urokinase containing a thrombin cleavable activating site. uPA-T prevented FeCl3-induced carotid arterial thrombosis in immunocompromized NOD/SCID, IL2 receptor γ-chain deficient (NSG) mice that had been pre-infused with human platelets (hPlts) without causing rebleeding from pre-existing tail-clips clots. However, this construct and subsequent hGPIIb-targeting scFv uPA-T chimeric constructs caused significant thrombocytopenia in hPlt-infused NSG (hPlt/NSG) mice and in hGPIIb+ mice. Therefore, we developed a new chimeric uPA-T targeting hGPIbα based on 5G6, a monoclonal antibody that binds to the hGPIbα juxtamembrane ADAM17 cleavage site and is known to not cause thrombocytopenia. The chimera 5G6/uPA-T binds to the surface of hPlts and hGPIbα-expressing mouse platelets at levels ~30% of those seen with hGPIIb/uPA-T, consistent with the difference in expression of GPIIb vs. GPIbα. 5G6/uPA-T did not reduce platelet counts in hPlt/NSG or hGPIα+ mice at doses that caused significant thrombocytopenia after infusion of GPIIb/uPA-T (1 mg/kg each, bolus + 30-minute infusion). We then tested the efficacy of 5G6/uPA-T in hPlt/NSG mice that that also carried a single mouse-to-human arginine (R) to histidine (H) substitution at position 1326 in von Willebrand factor, VWFH, created using CRISPR/Cas9 technology in NSG mice. This substitution, described by T. Diacovo (Megalion, Circulation 2011), markedly impairs binding of mouse Plts that express murine GPIbα, but increases the affinity for hPlt expressing hGPIbα. We hypothesized that such mice would allow studies of hPlt-enriched thrombi in mice. To test this hypothesis, hPlts were infused into NSG mice to achieve a circulating level of 10-20% of the total platelet pool. Following FeCl3-induced carotid arterial injury, similar numbers of hPlts were incorporated into the thrombi in wildtype VWFR/R NSG and heterozygous VWFR/H littermate NSG mice, whereas 1.4-1.8-fold more hPlts were incorporated in VWFH/H NSG littermates over the 3-minute observation period (n = 12-17, p Infusion of 5G6/uPA-T (1 mg/kg bolus+infusion) into hPlts-infused VWFH/H NSG mice prevented carotid artery thrombosis induced by FeCl3 and observed for 30 minutes as follows: In the absence of infused hPlts, 2/5 injured carotid arteries in the VWFH/H NSG mice completely occluded with a total flow volume in all vessels measured by Doppler of 1158±377 ml/min.s area under the curve (AUC). In contrast, 5/5 vessels occluded hPlts-infused VWFH/H NSG mice with an average time to occlusion of 13.0±3.4 mins and an AUC reduced to 692±75 ml/min.s (p In summary, we believe that 5G6/uPA-T combines a number of desirable features for a drug designed to prevent untoward platelet-mediated thrombosis: i. 5G6/uPA-T binds specifically to a hPlt-specific receptor, allowing targeted delivery to evolving thrombi while sparing established clots where it likely poorly penetrates into the thrombi. ii. The drug is effective even while binding to the base of the GPIbα chain near the platelet surface, where it also likely maintains GPIb/IX biology by limiting GPIbα cleavage, and does not cause thrombocytopenia. iii. Finally, 5G6/uPA-T delivers a form of urokinase that needs the co-presence of thrombin to become activated further limiting its activity to sites of evolving thrombi. These properties were demonstrated in an in vivo model that selectively incorporates hPlts. We believe that 5G6 may have clinical application in settings where there is a high risk for thrombosis, such as maintaining stent patency, while avoiding untoward lysis of previously established clots. Disclosures Li: Neoletix: Consultancy, Equity Ownership. Poncz:Incyte Corporation: Consultancy, Research Funding.
- Published
- 2018
27. Pleiotropic platelet defects in mice with disrupted FOG1-NuRD interaction
- Author
-
Gerd A. Blobel, Xiang Yu, Charles S. Abrams, Vincent Hayes, Rudy Fuentes, Yuhuan Wang, Harry F. G. Heijnen, Ronghua Meng, Michael S. Marks, and Mortimer Poncz
- Subjects
Blood Platelets ,Mice, 129 Strain ,P-selectin ,Immunology ,Biology ,Gray Platelet Syndrome ,Biochemistry ,Thrombopoiesis ,Gray platelet syndrome ,Mice ,Thrombin ,Megakaryocyte ,medicine ,Animals ,Point Mutation ,Platelet ,Nuclear Proteins ,GATA1 ,Cell Biology ,Hematology ,Platelets and Thrombopoiesis ,medicine.disease ,Molecular biology ,Mice, Mutant Strains ,Mice, Inbred C57BL ,Disease Models, Animal ,P-Selectin ,medicine.anatomical_structure ,Signal transduction ,Megakaryocytes ,Mi-2 Nucleosome Remodeling and Deacetylase Complex ,Signal Transduction ,Transcription Factors ,medicine.drug - Abstract
Understanding platelet biology has been aided by studies of mice with mutations in key megakaryocytic transcription factors. We have shown that point mutations in the GATA1 cofactor FOG1 that disrupt binding to the nucleosome remodeling and deacetylase (NuRD) complex have erythroid and megakaryocyte lineages defects. Mice that are homozygous for a FOG1 point mutation (ki/ki), which ablates FOG1-NuRD interactions, have platelets that display a gray platelet syndrome (GPS)–like macrothrombocytopenia. These platelets have few α-granules and an increased number of lysosomal-like vacuoles on electron microscopy, reminiscent of the platelet in patients with GATA1-related X-linked GPS. Here we further characterized the platelet defect in ki/ki mice. We found markedly deficient levels of P-selectin protein limited to megakaryocytes and platelets. Other α-granule proteins were expressed at normal levels and were appropriately localized to α-granule–like structures. Treatment of ki/ki platelets with thrombin failed to stimulate Akt phosphorylation, resulting in poor granule secretion and platelet aggregation. These studies show that disruption of the GATA1/FOG1/NuRD transcriptional system results in a complex, pleiotropic platelet defect beyond GPS-like macrothrombocytopenia and suggest that this transcriptional complex regulates not only megakaryopoiesis but also α-granule generation and signaling pathways required for granule secretion.
- Published
- 2011
28. Antibodies associated with heparin-induced thrombocytopenia (HIT) inhibit activated protein C generation: new insights into the prothrombotic nature of HIT
- Author
-
Sriram Krishnaswamy, Karine Amirikian, Lubica Rauova, Douglas B. Cines, Vincent Hayes, Richard H. Aster, Jeffrey D. Esko, Mortimer Poncz, Daniel W. Bougie, M. Anna Kowalska, and Li Zhai
- Subjects
Adult ,Protamine sulfate ,Thrombomodulin ,Protein C inhibitor ,Immunology ,Kidney ,Platelet Factor 4 ,Biochemistry ,Thrombosis and Hemostasis ,Mice ,chemistry.chemical_compound ,Thrombin ,Heparin-induced thrombocytopenia ,medicine ,Animals ,Humans ,Chondroitin sulfate ,Cells, Cultured ,Glycosaminoglycans ,Protein C Inhibitor ,Mice, Knockout ,Integrases ,Heparin ,Antibodies, Monoclonal ,Anticoagulants ,Kidney metabolism ,Cell Biology ,Hematology ,medicine.disease ,Thrombocytopenia ,Molecular biology ,Recombinant Proteins ,Mice, Inbred C57BL ,chemistry ,Prothrombin ,Protein Multimerization ,Platelet factor 4 ,Protein C ,medicine.drug - Abstract
Heparin-induced thrombocytopenia (HIT) is caused by antibodies that recognize complexes between platelet factor 4 (PF4) and heparin or glycosaminoglycan side chains. These antibodies can lead to a limb- and life-threatening prothrombotic state. We now show that HIT antibodies are able to inhibit generation of activated protein C (aPC) by thrombin/thrombomodulin (IIa/TM) in the presence of PF4. Tetrameric PF4 potentiates aPC generation by formation of complexes with chondroitin sulfate (CS) on TM. Formation of these complexes occurs at a specific molar ratio of PF4 to glycosaminoglycan. This observation and the finding that the effect of heparin on aPC generation depends on the concentration of PF4 suggest similarity between PF4/CS complexes and those that bind HIT antibodies. HIT antibodies reduced the ability of PF4 to augment aPC formation. Cationic protamine sulfate, which forms similar complexes with heparin, also enhanced aPC generation, but its activity was not blocked by HIT antibodies. Our studies provide evidence that complexes formed between PF4 and TM's CS may play a physiologic role in potentiating aPC generation. Recognition of these complexes by HIT antibodies reverses the PF4-dependent enhancement in aPC generation and may contribute to the prothrombotic nature of HIT.
- Published
- 2011
29. Cost Benefit and Break-Even Analysis of Screening for Non-Alcoholic Fatty Liver Disease Utilizing FibroScan as Compared to Usual Care
- Author
-
Woodie M. Zachry, David Halajko, Vincent Hayes, and Guy W. Neff
- Subjects
medicine.medical_specialty ,Hepatology ,business.industry ,Usual care ,Fatty liver ,Gastroenterology ,medicine ,Non alcoholic ,Cost benefit ,Disease ,Intensive care medicine ,medicine.disease ,business - Published
- 2018
30. Abstract 2818: AsiDNA and HDAC inhibitors: A cross-potentiation team working to kill tumor cells
- Author
-
Marie Dutreix, Jean-Louis Labernardière, Richard Tripelon, Françoise Bono Colombie, Laura Bellassen, Hélène Toussaint, Véronique Trochon-Joseph, Perrine Pivette, Coraline Cassegrain, Wael Jdey, and Vincent Hayes
- Subjects
Cancer Research ,biology ,Chemistry ,DNA damage ,DNA repair ,Cancer ,medicine.disease ,Comet assay ,chemistry.chemical_compound ,Histone ,Oncology ,Acetylation ,medicine ,Cancer research ,biology.protein ,Belinostat ,DNA - Abstract
Purpose: while being registered and used in restricted subset of T-cell lymphoma, HDAC inhibitors (HDACi) have shown limited antitumor effect as single agents. Recent studies have shown an effect of HDACi on DNA damage accumulation, rationalizing their combination with DNA repair inhibitors. In the current study, we propose a novel therapeutic strategy, based on drug combination of HDACi with the pan-DNA break repair inhibitor AsiDNA to promote their antitumor activity. Experimental design: AsiDNATM is a double stranded DNA molecule (decoy oligo-nucleotide) that mimics double stranded DNA breaks (DSBs) to interfere with DNA repair, redirecting repair enzymes away from sites of tumor DNA damage. Belinostat is a pan-HDACi displaying a better safety profile compared to other HDACi. We characterized the effects of each drug on DNA break accumulation and genetic instability by γH2AX analysis, COMET assay and micronuclei detection. We further studied the antitumor efficacy of the combination of the two drugs. Finally, we assessed the effect of AsiDNA on the occurrence of acquired resistance after long term treatment with belinostat. Results: Molecular analyses of DNA damage after treatment demonstrate that belinostat paves the way for AsiDNA efficacy by inducing DNA DSBs as measured by γH2AX accumulation and tail moment increase on COMET assay. Moreover, continuous treatment with belinostat induced an increase of basal genetic instability in tumor cells measured by micronuclei accumulation, a prerequisite for AsiDNA antitumor efficacy1. On the other hand, AsiDNA enhances the effects of belinostat on histone acetylation, demonstrating a high potentiation of belinostat activity on its targets by AsiDNA. This mechanism-based cross-potentiation between AsiDNA and belinostat results in a high synergistic antitumor efficacy of the combined treatment in different tumor models. This synergistic effect was further confirmed with several HDACi belonging to different classes. Importantly, the combined treatment do not induce any DNA damage increase and/or lethality in non-tumor cells. Finally, repeated treatments allowed the emergence of resistance to belinostat, which is abrogated in presence of AsiDNA, indicating an unlikely tumor escape to this combined therapy. Conclusion: Altogether these results indicate a cross potentiation between AsiDNA and belinostat, and support the rational to investigate the clinical activity of this novel synergistic combination in different tumor types. As belinostat has obtained FDA conditional approval, and AsiDNA is already tested in a first-in-man clinical trial, a potential exists for a rapid clinical confirmation of the interest of this new combination. Citation Format: Wael Jdey, Hélène Toussaint, Coraline Cassegrain, Laura Bellassen, Richard Tripelon, Vincent Hayes, Perrine Pivette, Véronique Trochon-Joseph, Jean-Louis Labernardière, Marie Dutreix, Françoise Bono Colombie. AsiDNA and HDAC inhibitors: A cross-potentiation team working to kill tumor cells [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2018; 2018 Apr 14-18; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2018;78(13 Suppl):Abstract nr 2818.
- Published
- 2018
31. Atomic description of the immune complex involved in heparin-induced thrombocytopenia
- Author
-
Zheng Cai, Mark I. Greene, Zhiqiang Zhu, Douglas B. Cines, Gowthami M. Arepally, Qun Liu, Lubica Rauova, Serge Yarovoi, Tatiana Lebedeva, Mortimer Poncz, and Vincent Hayes
- Subjects
Male ,Models, Molecular ,Antigen-Antibody Complex ,medicine.drug_class ,Protein Conformation ,General Physics and Astronomy ,Enzyme-Linked Immunosorbent Assay ,Mice, Transgenic ,Biology ,Monoclonal antibody ,Platelet Factor 4 ,General Biochemistry, Genetics and Molecular Biology ,Epitope ,Antibodies ,Article ,Autoimmune Diseases ,Mice ,Tetramer ,Heparin-induced thrombocytopenia ,medicine ,Animals ,Humans ,Platelet activation ,Glycosaminoglycans ,Mice, Knockout ,Multidisciplinary ,Heparin ,Anticoagulants ,General Chemistry ,medicine.disease ,Platelet Activation ,Molecular biology ,Thrombocytopenia ,Immune complex ,3. Good health ,Cell biology ,Mice, Inbred C57BL ,Gene Expression Regulation ,Immunoglobulin G ,Platelet factor 4 - Abstract
Heparin-induced thrombocytopenia (HIT) is an autoimmune thrombotic disorder caused by immune complexes containing platelet factor 4 (PF4), antibodies to PF4 and heparin or cellular glycosaminoglycans (GAGs). Here we solve the crystal structures of the: (1) PF4 tetramer/fondaparinux complex, (2) PF4 tetramer/KKO-Fab complex (a murine monoclonal HIT-like antibody) and (3) PF4 monomer/RTO-Fab complex (a non-HIT anti-PF4 monoclonal antibody). Fondaparinux binds to the ‘closed' end of the PF4 tetramer and stabilizes its conformation. This interaction in turn stabilizes the epitope for KKO on the ‘open' end of the tetramer. Fondaparinux and KKO thereby collaborate to ‘stabilize' the ternary pathogenic immune complex. Binding of RTO to PF4 monomers prevents PF4 tetramerization and inhibits KKO and human HIT IgG-induced platelet activation and platelet aggregation in vitro, and thrombus progression in vivo. The atomic structures provide a basis to develop new diagnostics and non-anticoagulant therapeutics for HIT., Heparin-induced thrombocytopenia (HIT) is an autoimmune thrombotic disease with limited treatment options. Here the authors present crystallographic data on the disease-causing immune complex, providing the structural basis for the development of new diagnostic and therapeutic approaches to HIT.
- Published
- 2015
32. Abstract 3076: A novel nanoparticle formulation of doxorubicin is clearly differentiated from free doxorubicin in overcoming resistance mechanisms in chemo-resistant tumors
- Author
-
Jean-Louis Labernardière, Vincent Hayes, Caroline Lemarchand, Véronique Trochon-Joseph, Séverine Rochas, Françoise Bono, Yamina Rayah, Graham Dixon, and Christelle Zandanel
- Subjects
Sorafenib ,Cancer Research ,Chemistry ,Cancer ,medicine.disease ,Gemcitabine ,chemistry.chemical_compound ,Oncology ,In vivo ,Pancreatic cancer ,medicine ,Cancer research ,Doxorubicin ,Erlotinib ,Lenvatinib ,medicine.drug - Abstract
Background and Aims. Chemo-resistance in hepatocellular carcinoma (HCC) tumor cells can be mediated by several mechanisms including P-gp efflux pumps and drug sequestration by the autophagy process. This study investigates the potential of doxorubicin loaded nanoparticle (NP) to reverse chemo-resistance by these mechanisms compared to free doxorubicin. We present the preclinical evaluation of anti-tumor effects of NP as monotherapy and in combination with standard agents used in treatment of HCC, pancreatic and sarcoma cancers. A phase III clinical study comparing NP to Best Standard of Care (Relive study) in patients with advanced HCC is in the final stages of recruitment with preliminary results expected in 2H 2017. Methods. Tumor cell lines were incubated with drugs in cell proliferation assay. In vivo efficacy of NP alone (4-8 mg/kg) or in combination with current and investigational treatments for pancreatic cancer (e.g. Gemcitabine, Erlotinib, Abraxane) and HCC (Sorafenib, Regorafenib and Lenvatinib) were performed in mouse tumor models using tumor weight as primary endpoint. In all experiments NP was compared to administration of free doxorubicin. Doxorubicin quantification in tumor and organs to asses PK and biodistribution was also performed using an LC/MS based method. Autophagy was measured by cell proliferation in the presence of inhibitors e.g.. Concanamycin A, Hydroxychloroquine sulfate added 30 min before incubation with the test compound. Results. NP showed a dose-dependent inhibition of cell proliferation in all resistant cancer cell lines tested with a superior activity compared to free doxorubicin and other tested drugs. In contrast to free doxorubicin, NP showed consistent anti-proliferative activity in the absence/presence of inhibitors of P-gp pumps and autophagy. In a range of in vivo models, NP was preferentially taken up by the tumor tissue and significantly reduced tumor growth when compared with free doxorubicin and with at least equivalent reduction in tumor growth compared to current treatments. Furthermore NP administered in combination with current treatments significantly increased the inhibitory effect of each drug without additional toxicity (as measured by no change in body weight). The results comparing efficacy of NP alone and in combination in HCC, pancreatic and sarcoma cancer models will be presented. Conclusions. These results demonstrate that NP is clearly differentiated from free doxorubicin, in 1) overcoming resistance mechanisms linked to efflux and autophagy, and 2) having a superior biodistribution profile both of which results in significantly enhanced activity on chemo-resistant tumors. NP also provides an opportunity to combine with other agents, enhancing activity without increasing toxicity. The implications of these results on the further development of NP will be discussed. Citation Format: Véronique Trochon-joseph, Christelle Zandanel, Caroline Lemarchand, Vincent Hayes, Séverine Rochas, Yamina Rayah, Jean-Louis Labernardière, Graham Dixon, Francoise Bono. A novel nanoparticle formulation of doxorubicin is clearly differentiated from free doxorubicin in overcoming resistance mechanisms in chemo-resistant tumors [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2017; 2017 Apr 1-5; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2017;77(13 Suppl):Abstract nr 3076. doi:10.1158/1538-7445.AM2017-3076
- Published
- 2017
33. Inducible Gata1 suppression expands megakaryocyte-erythroid progenitors from embryonic stem cells
- Author
-
David Finkelstein, Shilpa Gandre-Babbe, Paul Gadue, Jacob C. Ulirsch, Michael Kyba, Vijay G. Sankaran, Mortimer Poncz, Ji Yoon Noh, Yuhuan Wang, Yu Yao, Kellie R. Machlus, Joseph E. Italiano, Mitchell J. Weiss, Deborah L. French, Spencer K. Sullivan, Vincent Hayes, and Stella T. Chou
- Subjects
Cellular differentiation ,Biology ,Mice ,Megakaryocyte ,medicine ,Animals ,Humans ,GATA1 Transcription Factor ,Progenitor cell ,Induced pluripotent stem cell ,Thrombopoietin ,Embryonic Stem Cells ,Brief Report ,GATA1 ,Cell Differentiation ,General Medicine ,Embryonic stem cell ,Molecular biology ,Cell biology ,Anti-Bacterial Agents ,Haematopoiesis ,medicine.anatomical_structure ,Gene Expression Regulation ,Doxycycline ,Commentary ,Megakaryocytes ,Megakaryocyte-Erythroid Progenitor Cells - Abstract
Transfusion of donor-derived platelets is commonly used for thrombocytopenia, which results from a variety of clinical conditions and relies on a constant donor supply due to the limited shelf life of these cells. Embryonic stem (ES) and induced pluripotent stem (iPS) cells represent a potential source of megakaryocytes and platelets for transfusion therapies; however, the majority of current ES/iPS cell differentiation protocols are limited by low yields of hematopoietic progeny. In both mice and humans, mutations in the gene-encoding transcription factor GATA1 cause an accumulation of proliferating, developmentally arrested megakaryocytes, suggesting that GATA1 suppression in ES and iPS cell–derived hematopoietic progenitors may enhance megakaryocyte production. Here, we engineered ES cells from WT mice to express a doxycycline-regulated (dox-regulated) shRNA that targets Gata1 transcripts for degradation. Differentiation of these cells in the presence of dox and thrombopoietin (TPO) resulted in an exponential (at least 1013-fold) expansion of immature hematopoietic progenitors. Dox withdrawal in combination with multilineage cytokines restored GATA1 expression, resulting in differentiation into erythroblasts and megakaryocytes. Following transfusion into recipient animals, these dox-deprived mature megakaryocytes generated functional platelets. Our findings provide a readily reproducible strategy to exponentially expand ES cell–derived megakaryocyte-erythroid progenitors that have the capacity to differentiate into functional platelet-producing megakaryocytes.
- Published
- 2014
34. Clot contraction: compression of erythrocytes into tightly packed polyhedra and redistribution of platelets and fibrin
- Author
-
Walter Massefski, Chandrasekaran Nagaswami, Rustem I. Litvinov, Douglas B. Cines, Lubica Rauova, Tatiana Lebedeva, John W. Weisel, Vincent Hayes, and Thomas Jay Lowery
- Subjects
Blood Platelets ,Contraction (grammar) ,Erythrocytes ,Platelet Aggregation ,medicine.medical_treatment ,Immunology ,Biochemistry ,Fibrin ,Thrombosis and Hemostasis ,Mice ,Fibrinolysis ,medicine ,Animals ,Humans ,Platelet ,Thrombus ,Blood Coagulation ,biology ,Chemistry ,Thrombosis ,Cell Biology ,Hematology ,Anatomy ,medicine.disease ,Deuterium ,Coronary Vessels ,Hemostasis ,Biophysics ,biology.protein ,Wound healing ,Hydrogen ,circulatory and respiratory physiology - Abstract
Contraction of blood clots is necessary for hemostasis and wound healing and to restore flow past obstructive thrombi, but little is known about the structure of contracted clots or the role of erythrocytes in contraction. We found that contracted blood clots develop a remarkable structure, with a meshwork of fibrin and platelet aggregates on the exterior of the clot and a close-packed, tessellated array of compressed polyhedral erythrocytes within. The same results were obtained after initiation of clotting with various activators and also with clots from reconstituted human blood and mouse blood. Such close-packed arrays of polyhedral erythrocytes, or polyhedrocytes, were also observed in human arterial thrombi taken from patients. The mechanical nature of this shape change was confirmed by polyhedrocyte formation from the forces of centrifugation of blood without clotting. Platelets (with their cytoskeletal motility proteins) and fibrin(ogen) (as the substrate bridging platelets for contraction) are required to generate the forces necessary to segregate platelets/fibrin from erythrocytes and to compress erythrocytes into a tightly packed array. These results demonstrate how contracted clots form an impermeable barrier important for hemostasis and wound healing and help explain how fibrinolysis is greatly retarded as clots contract.
- Published
- 2014
35. Platelet Release from Infused CD34+-Derived Human Megakaryocytes: Lessons from a Natural-Occurring Platelet Bioreactor
- Author
-
Mortimer Poncz, Jing Dai, Danuta Jarocha, Lubica Rauova, Paul Kubes, Ian Johnston, and Vincent Hayes
- Subjects
Lung ,Immunology ,CD34 ,Cell Biology ,Hematology ,Biology ,Biochemistry ,Cell biology ,Glycocalyx ,medicine.anatomical_structure ,Megakaryocyte ,medicine ,Platelet ,Thrombopoiesis ,Bone marrow ,Intravital microscopy - Abstract
The release of biologically intact platelets from in vitro-grown megakaryocytes remains one of the challenges in an attempt to replace donor-derived platelets with platelets prepared from in vitro-grown megakaryocytes. Thrombopoiesis, the process by which megakaryocytes release platelets, is thought to occur as megakaryocytes exit from the medullar space and transit into the blood stream. Two-photon fluorescence microscopy studies by several groups have documented megakaryocytes transitioning into the blood stream and extending mostly a single protrusion that appears to release large cytoplasmic fragments downstream. These studies have been widely interpreted to support platelet release in the bone marrow environment. A counter proposal made by Dr. William Howell over 75 years ago is that either whole megakaryocytes or large cytoplasmic fragments circulate to the lungs and release platelets in the lungs. Studies by our group infusing in vitro-grown megakaryocytes (both human and mouse) have shown that infused megakaryocytes do indeed become entrapped in the lungs and release platelets. These in vivo-released platelets have a much longer half-life than in vitro-prepared platelets from static cultures and have the same size distribution and nearly the same functionality as infused donor-derived platelets. Using confocal intravital microscopy, we now directly visualized the lungs of recipient NOD-SCID interferon 2 receptor γ-deficient mice during the infusion of calcein-loaded CD34+-derived megakaryocytes. Infused human megakaryocytes were immediately arrested in the pulmonary bed in vessels ~50 µm in diameter. Each cell then extended several distinct protrusions winding down presumed pulmonary capillaries that are presumably wrapped around alveoli. Some of these protrusions reached 200-300 µm in length and assumed the appearance of beads on a string. Consistent with our recently published data, this thrombopoiesis process appears to take 30 minutes to be near-complete, similar to the timeframe we showed for detecting newly released human platelet-like particles after megakaryocyte infusion. At 30 minutes, remaining bodies of the megakaryocytes are still present and we presume these are mostly the remaining nuclei. To better define whether the pulmonary bed is unique for releasing platelets, we also infused megakaryocytes intra-arteriole rather than intravenously to have the megakaryocytes encounter other organ capillary beds before the lung. These studies showed poor platelet release compared to parallel studies in mice receiving the megakaryocytes intravenously. Many of the intra-arterial infused megakaryocytes were entrapped in the spleen and very few were notable in other organs, including the lungs, liver and kidney. Our studies showed that megakaryocytes can shed platelets in the lungs where they may take advantage of the unique three-dimensional organization of the pulmonary vascular bed, flow conditions, vascular surface receptors and glycocalyx as well as a sudden shift from hypoxic to normoxic conditions. Whether these features of the pulmonary vascular bed can be simulated ex vivo and whether this will enhance true platelet release from megakaryocytes in vitro needs to be examined. Disclosures No relevant conflicts of interest to declare.
- Published
- 2016
36. Enhancing Functional Platelet Release In Vivo from in Vitro-Grown Megakaryocytes Using the Protein Kinase Inhibitor SU6656
- Author
-
Mortimer Poncz, Karen K. Vo, Danuta Jarocha, Randolph B. Lyde, and Vincent Hayes
- Subjects
P-selectin ,medicine.diagnostic_test ,Chemistry ,medicine.drug_class ,Immunology ,Cell Biology ,Hematology ,Protein kinase inhibitor ,medicine.disease ,Biochemistry ,In vitro ,Flow cytometry ,Cell biology ,chemistry.chemical_compound ,SU6656 ,In vivo ,medicine ,Thrombus ,Annexin A5 - Abstract
The clinical demand for platelet transfusions is increasing, threatening the ability to obtain sufficient healthy donors to provide these platelets. Advances in regenerative medicine research have opened the possibility of generating sufficient in vitro-grown megakaryocytes and consequent platelets to supply a portion of the clinical platelet transfusion demand. We have shown that infusing megakaryocytes for obtaining released, functional platelets is a viable alternative strategy than trying to release platelets in vitro. However, for both approaches, in vitro-cultured megakaryocytes have lower ploidy and release fewer platelets than likely occurs in vivo by primary cells. SU6656 inhibitor, a Src kinase inhibitor, has been shown to influence ploidization in several megakaryocyte-like line with purported increase in proplatelets release. However, in our hands, other agents - such as the ROCK inhibitor Y27632 - while increasing polyploidization markedly, inhibited platelet release per infused megakaryocyte in vivo. We grew megakaryocytes from CD34+ cells for 12 days with or without SU6656 (2.5 µM) supplementation during the last 4 days. We found that the SU6656 inhibitor only increased the number of CD34+-derived megakaryocytes by ~15% at the end of the 12 day growth, but more markedly increase the percent of large megakaryocytes measured by FSC parameter in flow cytometry evaluation from 28 up to 41% and percent of high granular megakaryocytes from 27 to 45%. These changes were accompanied with a shift in average ploidy from 4.9 to 6.9 (p Disclosures No relevant conflicts of interest to declare.
- Published
- 2016
37. Cooperative integrin/ITAM signaling in platelets enhances thrombus formation in vitro and in vivo
- Author
-
Huiying Zhi, Cunji Gao, Mortimer Poncz, Debra K. Newman, Vincent Hayes, Peter J. Newman, Brian Boylan, Lubica Rauova, Steven E. McKenzie, and Brian C. Cooley
- Subjects
Blood Platelets ,Platelet Aggregation ,Immunology ,Integrin ,Syk ,Mice, Transgenic ,Platelet Glycoprotein GPIIb-IIIa Complex ,In Vitro Techniques ,Biochemistry ,Fibrin ,Veins ,Mice ,Immunoreceptor tyrosine-based activation motif ,medicine ,Animals ,Humans ,Platelet ,Thrombus ,Receptors, Immunologic ,Hemostasis ,biology ,Platelet Count ,Receptors, IgG ,Fibrinogen ,Thrombosis ,Cell Biology ,Hematology ,medicine.disease ,Cell biology ,Mice, Inbred C57BL ,Arterioles ,biology.protein ,Tyrosine ,Signal transduction ,Signal Transduction - Abstract
The integrin family is composed of a series of 24 αβ heterodimer transmembrane adhesion receptors that mediate cell-cell and cell-extracellular matrix interactions. Adaptor molecules bearing immunoreceptor tyrosine-based activation motifs (ITAMs) have recently been shown to cooperate with specific integrins to increase the efficiency of transmitting ligand-binding–induced signals into cells. In human platelets, Fc receptor γ-chain IIa (FcγRIIa) has been identified as an ITAM-bearing transmembrane receptor responsible for mediating “outside-in” signaling through αIIbβ3, the major adhesion receptor on the platelet surface. To explore the importance of FcγRIIa in thrombosis and hemostasis, we subjected FcγRIIa-negative and FcγRIIa-positive murine platelets to a number of well-accepted models of platelet function. Compared with their FcγRIIa-negative counterparts, FcγRIIa-positive platelets exhibited increased tyrosine phosphorylation of Syk and phospholipase Cγ2 and increased spreading upon interaction with immobilized fibrinogen, retracted a fibrin clot faster, and showed markedly enhanced thrombus formation when perfused over a collagen-coated flow chamber under conditions of arterial and venous shear. They also displayed increased thrombus formation and fibrin deposition in in vivo models of vascular injury. Taken together, these data establish FcγRIIa as a physiologically important functional conduit for αIIbβ3-mediated outside-in signaling, and suggest that modulating the activity of this novel integrin/ITAM pair might be effective in controlling thrombosis.
- Published
- 2012
38. Abstract 2143: Mechanistic study of the relative cytotoxicity of doxorubicin loaded nanoparticle formulation compared to free doxorubicin in hepatocellular carcinoma (HCC) cell lines
- Author
-
Graham Dixon, Véronique Trochon-Joseph, Caroline Lemarchand, Yamina Rayah, Jean-Louis Labernardière, and Vincent Hayes
- Subjects
Oncology ,Cancer Research ,medicine.medical_specialty ,ATPase ,Cell ,Genistein ,02 engineering and technology ,Endocytosis ,03 medical and health sciences ,chemistry.chemical_compound ,0302 clinical medicine ,Internal medicine ,medicine ,Doxorubicin ,Cytotoxicity ,biology ,Chemistry ,021001 nanoscience & nanotechnology ,medicine.anatomical_structure ,Mechanism of action ,Cell culture ,030220 oncology & carcinogenesis ,Cancer research ,biology.protein ,medicine.symptom ,0210 nano-technology ,medicine.drug - Abstract
Background and Aims Efficacy of doxorubicin encapsulated into a biodegradable network (NP) is currently studied in phase III compared to Best Standard of Care in patients with advanced HCC (Relive study). Preclinical studies demonstrated that NP allowed the reversion of chemo-resistance and enhanced cytotoxicity compared to free doxorubicin on resistant human hepatoma and mestastatic liver cells. In this study the mechanism of action of NP in overcoming HCC cellular resistance as well as the mechanisms of cellular uptake were investigated in representative cell lines. Methods Determination of IC20 of NP in the presence of influx drug inhibitors targeting endocytosis (clathrin or caveolae-dependent; sucrose and Genistein respectively), phagocytosis (LY-294002) or macropinocytosis (Cytochalasin D) were performed on two HCC cell lines (HuH7 and HepG2) using a proliferation assay. Each uptake inhibitor was added 30 min before incubation with NP on cultured cells for measurement of proliferation followed by cellular quantification of free doxorubicin by HPLC. The same assays were also performed using Verapamil as an inhibitor of the major multidrug resistance protein P-glycoprotein (P-gp). The P-gp ATPase activity in plasma membrane preparations from vehicle, doxorubicin and NP-treated cells was determined using the Pgp-Glo assay system. Results NP showed lower IC20 than free doxorubicin in HCC proliferation assays. None of the influx inhibitors used in combination with NP impaired the inhibitory effect of NP on the rate of proliferation of HCC cell lines. Similarly, Verapamil did not modulate the cellular potency of NP on the rate of proliferation in these cell lines. Doxorubicin quantification in cellular extracts and supernatant of NP-treated cells confirmed these results. Furthermore, NP had no effect on P-gp ATPase activity in isolated plasma membrane samples. Conclusions All these results demonstrated that NP did not enter into the HCC cell via an active transport mechanism, but by passive diffusion as occurs with free Doxorubicin. The absence of inhibition of the P-gp ATPase by NP implies that the Doxorubicin-nanoparticle conjugate (ion pair) probably ‘hinders’ the doxorubicin from being a substrate for the pump rather than by a direct interaction. The implication of these data on the role of NP in the treatment of HCC will be discussed. Citation Format: Véronique Trochon-joseph, Caroline Lemarchand, Vincent Hayes, Yamina Rayah, Jean-Louis Labernardière, Graham Dixon. Mechanistic study of the relative cytotoxicity of doxorubicin loaded nanoparticle formulation compared to free doxorubicin in hepatocellular carcinoma (HCC) cell lines. [abstract]. In: Proceedings of the 107th Annual Meeting of the American Association for Cancer Research; 2016 Apr 16-20; New Orleans, LA. Philadelphia (PA): AACR; Cancer Res 2016;76(14 Suppl):Abstract nr 2143.
- Published
- 2016
39. Membrane Remodeling By Pathogenic Antibodies Underlies Monocyte Activation in Heparin-Induced Thrombocytopenia
- Author
-
Daria Madeeva, Vincent Hayes, John W. Weisel, Mortimer Poncz, Lubica Rauova, Rustem I. Litvinov, Douglas B. Cines, and Izabella A. Andrianova
- Subjects
medicine.diagnostic_test ,Monocyte ,Immunology ,Cell Biology ,Hematology ,Heparan sulfate ,Biology ,Biochemistry ,Flow cytometry ,Cell biology ,Cell membrane ,chemistry.chemical_compound ,medicine.anatomical_structure ,chemistry ,medicine ,Platelet ,Platelet activation ,Cell activation ,Platelet factor 4 - Abstract
Heparin induced thrombocytopenia (HIT) is an iatrogenic antibody-mediated disorder with a paradoxically high propensity for thrombosis. We have shown previously that human HIT IgGs and the HIT-like monoclonal antibody (MAb) KKO bind to platelet factor 4 (PF4) complexed with glycosaminoglycans (GAGs) on the surface of platelets and monocytes, initiating cell activation in vitro, thrombocytopenia in a transgenic mouse model, and thrombus formation in a laser microvascular injury model in vivo even in the absence of exogenous heparin. Monocytes bind PF4 and HIT Ab more readily than platelets because they express higher affinity GAGs, heparan sulfate and dermatan sulfate, in addition to chondroitin sulfate found on both cell types. To study changes in the structure of the monocytes that accompany HIT, we used scanning electron microscopy, confocal microscopy and flow cytometry to characterize the morphology and function of isolated human monocytes and mouse transgenic Fcg receptor IIA positive (FcγRIIA+) or wt (FcγRIIA-) monocytes in the absence or presence of platelets. We show by scanning electron microscopy that upon binding of pathogenic HIT Abs to PF4/GAG complexes on FcgRIIA expressing monocytes, they initiate profound remodeling of the cell membrane. Addition of 100 μg/ml recombinant human PF4 in the absence of HIT Abs initiates the activation process with the appearance of 177 ± 53 nm "knobs" on the surface of 70% of monocytes. Subsequent addition of the HIT-like monoclonal antibody KKO at 50 μg/ml dramatically alters the cellular surface with the appearance of large 701 ± 208 nm membrane "blebs" that were not seen on FcγRIIA-mouse monocytes. These large, membrane-associated structures likely engage FcγRIIA, clustering them in proximity to cell-bound immune complexes, which promotes cell activation that leads to thrombosis. These blebs increase in size over time and are then shed from the cells as monocyte-derived microparticles, which self-aggregate. As a result of shedding of these blebs, the monocytes lose much of their typical ruffled surface (only 67% of monocytes maintain ruffles in the presence of PF4 plus KKO, compared to 97% of control monocytes) and appear smoother, sometimes with pores indicating degranulation. In the presence of platelets, monocytes exposed to PF4 and KKO formed heterocellular aggregates in addition to these subcellular changes. In contrast to KKO, addition of the non-pathogenic MAb RTO not only did not induce blebbing, but largely inhibited PF4-induced changes in the monocyte surface. This suggests that RTO might prevent monocyte activation by interfering with PF4 tetramerization. Structural analysis of the shed microparticles by microscopy revealed that they had an average diameter of 356 ± 307 nm, with many larger particles and aggregates. Flow cytometry confirmed that the shed particles contain cell membrane lipids and receptors. Confocal microscopy showed uniform binding of labeled PF4 to the monocyte cell membrane followed by rapid clustering into large complexes after the addition of KKO, but not RTO. These studies affirm the centrality of cell surface PF4/GAG complexes in the pathogenesis of HIT and provide quantitative morphometric characteristics of the changes in the monocyte membrane structure. We propose that PF4 released from activated platelets binds to the surface of GAG-expressing monocytes in vivo, forming clusters of PF4/GAG complexes that likely promote antibody binding and cause monocyte activation through FcγRIIA along with large-scale remodeling of the cell membrane and shedding of procoagulant microparticles. Disclosures No relevant conflicts of interest to declare.
- Published
- 2015
40. A Targeted Photochemical Microfluidic Vascular Injury Model for in Vitro Thrombosis Studies: Usage in Heparin-Induced Thrombocytopenia (HIT)
- Author
-
Mortimer Poncz, Ian Johnston, Vincent Hayes, and Douglas B. Cines
- Subjects
Chemistry ,Immunology ,Inflammation ,Cell Biology ,Hematology ,Heparin ,medicine.disease ,Photochemistry ,Biochemistry ,Heparin-induced thrombocytopenia ,medicine ,Platelet ,Platelet activation ,Thrombus ,medicine.symptom ,Platelet factor 4 ,medicine.drug ,Whole blood - Abstract
Replicating the complexities of the human blood vessel include the establishment of a 3-D confluency of viable endothelial cells (ECs) on an appropriate matrix, use of human whole blood or specific components of blood, varied shear stresses, and the induction of a localized and controlled injury within the observable field to understand and intervene in hemostatic events. This array of complexities have made vascular modeling an important unmet challenge. Such a model would enhance our understanding of the pathogenesis of diverse coagulation disorders, such as the prothrombotic disorder HIT. In HIT, the platelet-rich clots lead to its other designation as the "white clot syndrome". To provide an improved injury model, we adapted a hematoporphyrin-photochemical injury using a Fluxion Bioflux microfluidic system. When illuminated with 405 nm light, hematoporphyrin releases reactive oxygen species, inducing localized EC injury within the exposed field, but without denuding ECs. Unlike rose bengal, hematoporphyrin does not cause fluorescent interference with quantitative analysis of the developing thrombus. We propose that the model permits refined analysis of ECs transitioning from areas of quiescence to injury to quiescence, allowing us to localize and quantify the contribution of various components to the growing thrombus. In HIT, patients form antibodies to complexes of the platelet-specific chemokine, platelet factor 4 (PF4), and negatively-charged molecules such as infused heparin and heparans found on the surface of platelets and monocytes. ECs also bind PF4 immune complexes due to their highly negatively charged glycocalyx-rich surface. Prior murine cremaster laser injury studies showed that HIT antibodies bind predominantly to the EC surface rather than platelet within the thrombus itself. Was this observation related to the nature of the cremaster injury? Would antibody binding to the EC lining also be important in a wholly human HIT detection system? Using the described photochemical microfluidic system, we created a localized injury in human umbilical vein EC-lined channels through which we flowed whole human blood. Activated platelets established growing aggregates at the site of EC injury, releasing more PF4 that then bound to non-activated ECs downstream of the injury. Whole blood containing a HIT-like antibody to simulate the prothrombotic state of HIT was then flowed over this injured vasculature. HIT antibodies and then platelets bound sequentially to this new site of HIT antigen, allowing the thrombus to propagate downstream. We have named this phenomenon "rolling barrage" and suggest that a key part of the prothrombotic nature of HIT lies in antibody-mediated activation of downstream EC with subsequent thrombus propagation. HIT often occurs in the setting in surgery, which might prime EC dysfunction. We therefore treated the ECs (TNF-α) prior to injury and introducing the HIT-like antibody. TNF-α activated the EC lining, leading to loss of the anticoagulant EC surface, which enhanced clot formation downstream of the site of photochemical injury. Therefore, in a prothrombotic state such as HIT, we propose that a local injury acts as a nidus for thrombus initiation. The procoagulant process spreads distally in part because of released PF4 adhering to the downstream EC glycocalyx, which is exacerbated by mediators of inflammation. We anticipate that the described model can be used to study novel interventions to block this cycle in a wholly human system with control over the contribution of individual cellular elements, and will further understanding of the importance of this mechanism in other prothrombotic disorders. Disclosures No relevant conflicts of interest to declare.
- Published
- 2015
41. The Second CGHC Motif of Protein Disulfide Isomerase Mediates Thrombosis
- Author
-
Lu Wang, Vincent Hayes, Yi Wu, Junsong Zhou, Lubica Rauova, David W. Essex, and Mortimer Poncz
- Subjects
inorganic chemicals ,biology ,P-selectin ,Chemistry ,Immunology ,Active site ,Cell Biology ,Hematology ,Biochemistry ,Fibrin ,In vitro ,nervous system diseases ,Cell biology ,body regions ,In vivo ,biology.protein ,Platelet ,Secretion ,Protein disulfide-isomerase - Abstract
Protein disulfide isomerase (PDI) catalyzes thiol-disulfide exchange reactions that are critical for protein function. PDI has two distinct CGHC redox-active sites, but nothing is known about which site is important in physiologic reactions including thrombosis. To study the role of PDI and its active sites in thrombosis we used two genetically-modified models, Mx1-Cre/PDIfl/fl mice with blood cells and vessel wall cells lacking PDI, and transgenic PDI(ss-oo) mice with PDI lacking the second CGHC active site. Using laser-induced cremaster arteriole injury fibrin deposition was decreased in both mouse models. Both mouse models showed attenuation of platelet accumulation using laser arterial injury and FeCl3-induced mesenteric artery injury. The defects in fibrin deposition and platelet accumulation were rescued by infusion of recombinant PDI(oo-ss) containing only a functional second active site, confirming the second active site of PDI was critical for both fibrin formation and platelet accumulation. In vitro studies showed that platelet aggregation depended on the second CGHC motif of PDI, and that binding of PDI protein to platelets depended on the presence of the αIIbβ3 integrin. Studies on platelet secretion revealed that P-selectin expression and ATP release were dependent on a functional second active site of PDI. Treatment of the platelets with eptifibatide did not affect P-selectin expression. Together these findings suggest the second active of PDI catalyzes a reaction in αIIbβ3 supporting platelet aggregation and a reaction in a non-αIIbβ3 substrate supporting secretion. In vivo studies on coagulation showed that PDI infusion rescued fibrin formation in eptifibatide-treated mice in which platelet accumulation was completely blocked, suggesting that PDI directly contributes to activation of coagulation. In summary, our results indicate that the second CGHC active site of PDI has a role in platelet function and coagulation. Targeting this site may have a dual inhibitory effect on thrombosis by decreasing both platelet and fibrin accumulation. Disclosures No relevant conflicts of interest to declare.
- Published
- 2015
42. Monocyte-bound PF4 in the pathogenesis of heparin-induced thrombocytopenia
- Author
-
Douglas B. Cines, Lubica Rauova, Li Zhai, M. Anna Kowalska, Teshell K. Greene, Jessica Hirsch, Mortimer Poncz, and Vincent Hayes
- Subjects
Immunology ,Inflammation ,Mice, Transgenic ,Platelet Factor 4 ,Biochemistry ,Autoantigens ,Monocytes ,Thrombosis and Hemostasis ,Pathogenesis ,Mice ,Heparin-induced thrombocytopenia ,medicine ,Animals ,Humans ,Platelet ,Thrombus ,Autoantibodies ,Glycosaminoglycans ,business.industry ,Heparin ,Monocyte ,Anticoagulants ,Cell Biology ,Hematology ,medicine.disease ,Thrombocytopenia ,medicine.anatomical_structure ,medicine.symptom ,business ,Platelet factor 4 ,medicine.drug ,Protein Binding - Abstract
Heparin-induced thrombocytopenia (HIT) is a life- and limb-threatening thrombotic disorder that develops after exposure to heparin, often in the setting of inflammation. We have shown previously that HIT is associated with antibodies to complexes that form between platelet factor 4 and glycosaminoglycan (GAG) side chains on the surface of platelets. However, thrombosis can occur in the absence of thrombocytopenia. We now show that platelet factor 4 binds to monocytes and forms antigenic complexes with their surface GAG side chains more efficiently than on platelets likely due to differences in GAG composition. Binding to monocytes is enhanced when the cells are activated by endotoxin. Monocyte accumulation within developing arteriolar thrombi was visualized by situ microscopy. Monocyte depletion or inactivation in vivo attenuates thrombus formation induced by photochemical injury of the carotid artery in a modified murine model of HIT while paradoxically exacerbating thrombocytopenia. These studies demonstrate a previously unappreciated role for monocytes in the pathogenesis of arterial thrombosis in HIT and suggest that therapies targeting these cells might provide an alternative approach to help limit thrombosis in this and possibly other thrombotic disorders that occur in the setting of inflammation.
- Published
- 2010
43. Inducible Gata1 Suppression As a Novel Strategy to Expand Physiologic Megakaryocyte Production from Embryonic Stem Cells
- Author
-
Kellie R. Machlus, Vikram R Paralkar, Paul Gadue, Ji-Yoon Noh, Mitchell J. Weiss, Mortimer Poncz, Yu Yao, Vincent Hayes, Michael Kyba, Spencer K. Sullivan, Deborah L. French, Joseph E. Italiano, Shilpa Gandre-Babbe, Stella T. Chou, and Yuhuan Wang
- Subjects
Immunology ,GATA1 ,Cell Biology ,Hematology ,Biology ,Biochemistry ,Cell biology ,Haematopoiesis ,medicine.anatomical_structure ,Megakaryocyte ,medicine ,Platelet activation ,Induced pluripotent stem cell ,Thrombopoietin ,Interleukin 3 ,Megakaryopoiesis - Abstract
Embryonic stem (ES) and induced pluripotent stem (iPS) cells represent potential sources of megakaryocytes and platelets for transfusion therapy. However, most current ES/iPS cell differentiation protocols are limited by low yields of hematopoietic progeny, including platelet-releasing megakaryocytes. Mutations in the mouse and human genes encoding transcription factor GATA1 cause accumulation of proliferating, developmentally arrested megakaryocytes. Previously, we reported that in vitro differentiation of Gata1-null murine ES cells generated self-renewing hematopoietic progenitors termed G1ME cells that differentiated into erythroblasts and megakaryocytes upon restoration of Gata1 cDNA by retroviral transfer. However, terminal maturation of Gata1-rescued megakaryocytes was aberrant with immature morphology and no proplatelet formation, presumably due to non-physiological expression of GATA1. We now engineered wild type (WT) murine ES cells that express doxycycline (dox)-regulated Gata1 short hairpin (sh) RNAs to develop a strategy for Gata1-blockade that upon its release, restores physiologic GATA1 expression during megakaryopoiesis. In vitro hematopoietic differentiation of control scramble shRNA-expressing ES cells with dox and thrombopoietin (TPO) produced megakaryocytes that underwent senescence after 7 days. Under similar differentiation conditions, Gata1 shRNA-expressing ES cells produced immature hematopoietic progenitors, termed G1ME2 cells, which replicated continuously for more than 40 days, resulting in ~1013-fold expansion (N=4 separate experiments). Upon dox withdrawal with multi-lineage cytokines present (EPO, TPO, SCF, GMCSF and IL3), endogenous GATA1 expression was restored to G1ME2 cells followed by differentiation into erythroblasts and megakaryocytes, but no myeloid cells. In clonal methylcellulose assays, dox-deprived G1ME2 cells produced a mixture of erythroid, megakaryocytic and erythro-megakaryocytic colonies. In liquid culture with TPO alone, dox-deprived G1ME2 cells formed mature megakaryocytes in 5-6 days, as determined by morphology, ultrastructure, acetylcholinesterase staining, upregulated megakaryocytic gene expression (Vwf, Pf4, Gp1ba, Selp, Ppbp), CD42b surface expression, increased DNA ploidy and proplatelet production. Compared to G1ME cells rescued with Gata1 cDNA retrovirus, dox-deprived G1ME2 cells exhibited more robust megakaryocytic maturation, similar to that of megakaryocytes produced from cultured fetal liver. Importantly, G1ME2 cell-derived megakaryocytes generated proplatelets in vitro and functional platelets in vivo (~40 platelets/megakaryocyte with a circulating half life of 5-6 hours). These platelets were actively incorporated into growing arteriolar thrombi at sites of laser injury and subsequently expressed the platelet activation marker p-selectin (N=3-4 separate experiments). Our findings indicate that precise timing and magnitude of a transcription factor is required for proper terminal hematopoiesis. We illustrate this principle using a novel, readily reproducible strategy to expand ES cell-derived megakaryocyte-erythroid progenitors and direct their differentiation into megakaryocytes and then into functional platelets in clinically relevant numbers. Disclosures No relevant conflicts of interest to declare.
- Published
- 2014
44. Comparative Analysis of Infused 'Static', Ex Vivo-Generated Platelets Vs. Infused Megakaryocytes-Generated Platelets: A Cautionary Tale
- Author
-
Danuta Jarocha, Vincent Hayes, Yuhuan Wang, and Mortimer Poncz
- Subjects
P-selectin ,Chemistry ,Immunology ,Convulxin ,Cell Biology ,Hematology ,Biochemistry ,Andrology ,medicine.anatomical_structure ,Megakaryocyte ,In vivo ,medicine ,Platelet ,Thrombopoiesis ,Progenitor cell ,Ex vivo - Abstract
Ex vivo-generated (EV) platelets beginning with embryonic stem cells or induced pluripotent stem cells (iPSCs) or hematopoietic progenitors cells (HPCs) may have clinical utility over donor-derived platelets, and efforts to produce such EV-platelets have been pursued in several laboratories under static megakaryocyte (Meg) culture conditions. Success in generating these has been reported, even demonstrating EV-platelet incorporation into growing thrombi in murine models. We have pursued an alternative strategy for thrombopoiesis using EV-Megs, grown from either human adult HPCs or from iPSCs or fetal livers, and directly infusing them into NOD-SCID gamma-interferon-deficient (NSG) mice. These studies were based on our prior observation that infused murine EV-Megs into wildtype mice are entrapped in the pulmonary bed and over the subsequent 1-4 hours release a wave of functional platelets at a significant level. We now show that infusion of human EV-Megs do the same in NSG mice, but resulting in two different pools of derived platelets: (1) A pool of young (as determined by thiazole orange staining) platelets having the same bell-shaped size distribution was seen as after infusion of human donor-derived platelets in these mice. These platelets take several hours to appear, but then have the same half-life as donor-derived platelets. These platelets are derived from the infused EV-Megs and were termed in vivo-generated (IV)-platelets. (2) A second pool of mostly older platelets was present that originated during the static growth of the EV-Megs, and these EV-platelets varied widely in size and age. Initially, these platelets accounted for a third of all the human platelets seen. Unlike IV-platelets, EV-platelets are immediately present and circulate with a markedly short half-life of 2-3 hours unless the recipient NSG mice were pre-treated with clodronate-ladened liposomes to delete their macrophage pools. Rapid removal of EV-platelets by macrophages is due to their being preactivated as determined by surface P-selectin expression in whole mice blood. These EV-platelets also had very limited further responsiveness to convulxin activation. On the other hand, human IV-platelets were quiescent prior to agonist stimulation in whole mice blood and responded strongly to agonist, similar to human donor-derived platelets infused into NSG mice. The IV-platelets were also selectively incorporated into cremaster arteriole laser injury thrombi over EV-platelets. Finally, directly harvested “platelets” from EV static-grown Megs were isolated and analyzed both in vitro and in vivo. Only a third of these particles are CD41+/CD42+ platelets and approximately half are actually CD41-/CD42-. Both pools showed the same wide size distribution in vitro and in vivo after infusion into mice. The CD41+/CD42+ fraction behaved just as the EV-platelets, but the CD41-/CD42- fraction half-life was unaffected by pre-treatment with clodronate-ladened liposomes. In summary, infused human Megs grown under static growth conditions released platelets in a recipient mouse’s lung with features characteristic of donor-derived platelets. On the other hand, “platelets” harvested from the same Megs were predominantly not even platelets as measured using CD41/CD42 markers. The portion that were CD41+/CD42+ platelets were preactivated, poorly responsive to agonists, and cleared rapidly. These findings set a standard on how to judge the potential clinical value of platelets derived from EV-Megs and also raise concerns whether direct visual imaging of “platelet release” in static culture is biologically meaningful given that most particles released were not CD41+/CD42+ platelets, and the ones that were CD41+/CD42+ were mis-sized and functionally limited. Disclosures No relevant conflicts of interest to declare.
- Published
- 2014
45. New Insights into the Prothrombotic State of Heparin-Induced Thrombocytopenia (HIT) Using a Novel Microfluidic System: The Endothelial Lining and 'Rolling Barrage' of Activation
- Author
-
Vincent Hayes, Ian Johnston, Mortimer Poncz, Douglas B. Cines, and Lubica Rauova
- Subjects
Endothelium ,Chemistry ,Immunology ,Cell Biology ,Hematology ,Heparin ,medicine.disease ,Biochemistry ,Cell biology ,Glycocalyx ,medicine.anatomical_structure ,Platelet degranulation ,Heparin-induced thrombocytopenia ,medicine ,Platelet ,Thrombus ,Platelet factor 4 ,medicine.drug - Abstract
The most feared feature of HIT is antibody-mediated thrombosis. We have shown that this prothrombotic state is related to binding of platelet factor 4 (PF4), a chemokine densely packaged into platelet alpha-granules, to surface glycosaminoglycans (GAGs) expressed on hematopoietic and vascular cells. PF4/GAG surface complexes are recognized by HIT antibodies, activating the targeted cells. Unlike platelets that express only low-affinity chondroitin sulfate surface GAGs, endothelial cells (EC) express a glycocalyx enriched in heparan sulfate, which has higher affinity for PF4, potentially increasing their propensity to become a target for immune injury leading to thrombosis. We examined the details of the development of in situ thrombi using the cremaster arteriole laser injury model beginning with transgenic mice expressing only human PF4 (hPF4+), but lacking FcγRIIA. These mice do not develop thrombocytopenia or thrombosis when injected with the HIT-like monoclonal antibody KKO or IgGs isolated from patients with HIT. In these mice, antigenic PF4/GAG complexes were recognized by KKO at sites of vascular injury even in the absence of infused heparin. In fact, infusion of sufficient heparin dissociated PF4 from sites of injury, consistent with its higher affinity for PF4 than cell surface GAGs. This suggests that antigenic PF4/GAG complexes normally develop intravascularly whenever thrombus formation occurs, yet these complexes do not typically initiate antibody-mediated thrombosis. Real-time confocal imaging of injured vessels revealed that PF4 first bound almost exclusively to the peri-injury endothelium. This was especially evident immediately upstream of the thrombus where turbulent blood flow may lead to platelet degranulation and subsequent adherence of the released PF4 to the glycocalyx. Beginning approximately two minutes post-injury, binding of KKO, presumably to PF4/GAG complexes on platelets, is seen at the interface between the shell and core of the thrombus. We then repeated these same studies in hPF4+/FcγRIIA+ mice, where infused KKO or HIT IgGs leads to significant thrombocytopenia and widespread development of thrombi as in HIT. Similar adherence of PF4 to the peri-injury EC and then to the core/shell interface of the thrombus as seen in the hPF4+ mice, but the changes were more extensive in hPF4+/FcγRIIA+ mice after KKO infusion and often lead to vascular occlusion. To further define the basis of the prothrombotic state in HIT and to extend our studies to a human system, we examined thrombus formation in HIT in a novel microfluidic system in which vascular injury was induced in an upstream portion of a human umbilical vein EC-lined channel by reactive oxygen species generated through excitation of infused hematoporphyrin by blue light (490 nm). Following infusion of human blood, platelets accumulated and released PF4, which bound the injured endothelium, while the downstream endothelium remained quiescent. Addition of KKO to the infused whole blood lead to a HIT-like state with marked increase in platelet adhesion and binding of PF4 to the injured endothelium, but binding of PF4 now spread downstream of the boundary between injured and uninjured endothelium. This was followed by downstream platelet adhesion and often occlusion of the channel. We proposed that this spread in EC injury was a result of a “rolling barrage” of PF4 released from platelets binding to the injured patch of EC complexing to the downstream glycocalyx on the non-injured endothelium followed by KKO binding and subsequent endothelial activation. The newly activated ECs bound additional platelets and the process repeats, rolling downstream and extending thrombus growth. Thus, these studies provide important new insights into the local sequence of events that propagate clots in HIT: Targeting of the endothelial glycocalyx by HIT antibodies is a major contributor to the prothrombotic state. Platelets adherent to the site of original injury release PF4, which then binds to downstream EC glycocalyx and initiates repetitive cycles of PF4 binding, EC activation and platelet adherence, and further release of PF4 that propagates growth of thrombi to previously uninvolved vasculature. Disclosures No relevant conflicts of interest to declare.
- Published
- 2014
46. A Human-Specific, Platelet-Targeted, Thrombin-Activatable Urokinase (PLT/uPA-T) Demonstrates Selective Thromboprophylactic Properties in Two in Vivo Models
- Author
-
Rudy Fuentes, Douglas B. Cines, Sergei Zaytsev, Vladimir R. Muzykantov, Mortimer Poncz, Vincent Hayes, and Hyun Sook Ahn
- Subjects
Urokinase ,Plasmin ,business.industry ,Immunology ,Cell Biology ,Hematology ,Pharmacology ,medicine.disease ,Biochemistry ,Bolus (medicine) ,Thrombin ,In vivo ,medicine ,Platelet ,Thrombus ,business ,Fibrinolytic agent ,medicine.drug - Abstract
Two major clinical limitations to the use of thrombolytic agents are their short half-life and lack of targeting specificity. We aimed to circumvent these limitations by targeting a platelet-bound, thrombin-activatable, low molecular weight urokinase, termed PLT/uPA-T, to nascent thrombi by a combination of two strategies: (1) Attaching the drug through its N-terminal scFv portion to human αIIb/β3 on the surface of platelets with nM affinity. (2) Protecting the uPA from rapid activation/inactivation in the circulation while simultaneously requiring its activation by thrombin through a two amino acid deletion at the plasmin cleavage site that concurrently creates a thrombin cleavage/activation site. These two properties constrain the activity of PLT/uPA-T on mature clots, which express low levels of thrombin and transiently recruit only a few new platelets to the shell rather than the core of the thrombus. These two properties of PLT/uPA-T also enhance the drug’s lifespan by attaching it to the platelet cell surface and preventing its inactivation before reaching its intended target. PLT/uPA-T binds specifically to human platelets and to hαIIb mouse platelets that transgenically expressed human (h) αIIb on its surface. In hαIIb mice, the half-life of retro-orbitally infused PLT/uPA-T was ~2 hours, ~100-fold longer than similarly infused uPA-T and did not cause any spontaneous bleeding or lower platelet counts 4 to 24 hours later. We now report two in vivo models to test the efficacy of the PLT/uPA-T as a thromboprophylactic agent versus uPA-T, taking into account the much shorter circulating half-life of the latter. In the hαIIb mice model, a tail-vein clipping model was done to represent the “mature clot” as follows: following clipping, blood was collected into 37°C water for 10 minutes. The tail was then removed from the water and a bolus of PLT/uPA-T (0.5 µg/g mouse) injected retro-orbitally followed by a continuous infusion of the same dose over the next 30 minutes. uPA-T was similarly infused but both bolus and infusion were given at 10-fold higher doses. A no-drug treatment control was also included. After the drug infusion was started, the tail was placed into fresh 37°C water and bleeding was documented from these “mature clots” over the ensuing 30 minutes. To study “nascent thrombi”, mice were bolused/infused with same drug regimens, and a FeCl3 carotid artery injury study was performed contemporaneously. PLT/uPA-T was as effective at 1/10th the dose as uPA-T at preventing these “nascent thrombi” (FeCl3 injuries), but did not cause bleeding from “mature clots” (tail clippings) relative to the no-treatment control, while the uPA-T treatment lead to ~5-fold greater rebleeding compared to the no-treatment control (p 10 animals per arm. The second in vivo model targeted human platelets infused into immunocompromized NOD-SCID γ-interferon-deficient (NSG) male mice to generate a calculated 10% of all the circulating platelets being human at the initiation of the studies. The pre-drug “mature clots” and the post-drug “nascent thrombi” were both arteriolar laser cremaster injuries. We enumerated mouse platelets incorporated into these thrombi over time. There was an ~50% decrease in the size of laser-induced post-drug “nascent thrombi” after PLT/uPA-T or a 10-fold higher dose of uPA-T relative to no drug treatment. However, PLT/uPA-T did not affect the size of the laser-induced pre-drug “mature clots” relative to no drug-treatment, while there was a decrease in size of the mature clots after treatment with uPA-T. These studies describe two preclinical models of comparative thromboprophylactic efficacy and safety that are independent of drug half-life. Our studies demonstrate that a combination of platelet-targeting and need for thrombin-activation makes PLT/uPA-T a very potent and targeted thrombolytic agent to prevent new thrombus formation, while leaving older, hemostatic clots intact. Disclosures No relevant conflicts of interest to declare.
- Published
- 2014
47. Polyhedrocytes: Compressed Polyhedral Erythrocytes In Contracted Blood Clots and Thrombi
- Author
-
John W. Weisel, Douglas B. Cines, Tatiana Lebedeva, Lubica Rauova, Vincent Hayes, Rustem I. Litvinov, Chandrasekaran Nagaswami, Thomas Jay Lowery, and Walter Massefski
- Subjects
Pathology ,medicine.medical_specialty ,Contraction (grammar) ,biology ,Chemistry ,medicine.medical_treatment ,Immunology ,Cell Biology ,Hematology ,Biochemistry ,Fibrin ,Thrombin ,Hemostasis ,Fibrinolysis ,medicine ,biology.protein ,Platelet ,Wound healing ,circulatory and respiratory physiology ,Whole blood ,medicine.drug - Abstract
Background Contraction of blood clots is necessary for hemostasis, wound healing and to restore flow past obstructive thrombi. However, little has been known about the structure of contracted clots and mechanisms of contraction. Erythrocytes, biconcave cells that are highly deformable to allow their passage through the microvasculature, are abundant in venous thrombi, and to a lesser extent in arterial thrombi. Erythrocytes promote hemostasis, but their participation in clot contraction has not been reported. Here we study the mechanisms of clot contraction and the roles of erythrocytes, platelets and fibrin, and show that erythrocyte shape change into compressed polyhedrocytes allows tight packing consistent with the major function of clots to stem bleeding. Methods Whole blood was clotted by recalcification and addition of thrombin or kaolin, while following the process of clotting, including contraction, with a new technique using T2 magnetic resonance. We examined the structure and composition of contracted whole blood clots by scanning electron microscopy and confocal light microscopy. Results Contracted clots display a remarkable structure, with a close-packed, tessellated array (or mosaic tiling of space) of compressed polyhedral erythrocytes (called polyhedrocytes) on the interior and a meshwork of fibrin and platelet aggregates on the exterior. Little fibin and few platelets were found on the interior of the contracted clots. The same results were obtained with both thrombin and kaolin as activators of clotting and also with reconstituted human blood and clots prepared from mouse blood. Confocal microscopy of hydrated clots confirms the results of scanning electron microscopy. The mechanical nature of this shape change was confirmed by polyhedrocyte formation from the forces of centrifugation of blood without clotting. Platelets (with their cytoskeletal motility proteins) and fibrin(ogen) (as the substrate bridging platelets for contraction) are required to generate the forces necessary to segregate platelets/fibrin from erythrocytes and to compress erythrocytes into a closely packed polyhedral array. To assess the density of packing of the polyhedral erythrocytes, we replaced the water surrounding the clots with D2O and observed by T2 magnetic resonance that hydrogen/deuterium exchange for the contracted clots was very slow, consistent with their very tightly packed, almost impermeable structure. The same polyhedrocyte structures were observed from in vivo thrombi aspirated by cardiologists from the coronary arteries of ST-elevation myocardial infarction patients. Summary/Conclusions We have observed a previously undiscovered, naturally occurring erythrocyte function and morphology, closely packed polyhedra, in contracted clots and thrombi, and an unexpected spatial redistribution of platelets and fibrin that occurs during contraction. Clot contraction is an essential part of hemostasis, since both human genetic disorders of platelet myosin IIA and megakaryocyte myosin IIA-knock out mice show a bleeding phenotype. These observations on contracted clots imply that they are stiff, rigid structures that can form an impermeable, watertight seal. On the one hand, contraction of clots within the vasculature may relieve obstruction of blood vessels and allow recanalization, especially in the venous system. On the other hand, these results account for long-standing clinical observations that fibrinolysis is greatly prolonged following clot contraction, since perfusion or diffusion of lytic enzymes into these tightly packed polyhedral erythrocytes would be nearly impossible. These results suggest a vital role for erythrocytes and clot contraction in hemostasis and wound healing. Disclosures: No relevant conflicts of interest to declare.
- Published
- 2013
48. Insights Into Thrombopoiesis From Infused Human Megakaryocytes Into Mice
- Author
-
Yuhuan Wang, Mortimer Poncz, Vincent Hayes, Stella T. Chou, Prasuna Paluru, and Deborah L. French
- Subjects
Interferon type II ,Platelet maturation ,Immunology ,Endogeny ,Cell Biology ,Hematology ,Nod ,Biology ,Biochemistry ,Andrology ,In vivo ,medicine ,Distribution (pharmacology) ,Platelet ,Thrombopoiesis ,medicine.drug - Abstract
Thrombopoiesis is the process by which megakaryocytes (Megs) release platelets (Plts), but issues remain as to the detailed in vivo mechanisms underlying this process. We now report new insights into this process by studying infused human Megs into immunocompromized NOD/SCID, gamma-interferon deleted (NSG) mice. Prior in situ microscopy has suggested that Megs release varied-size cytoplasmic fragments up to whole Megs in size into the medullary vascular space. Other studies have suggested that at least a portion of thrombopoiesis occurs by Megs lodged in the lungs. We previously infused ex vivo-generated murine Megs into mice and found that these Megs become entrapped in the animals’ lungs, and in Disclosures: No relevant conflicts of interest to declare.
- Published
- 2013
49. Role Of Monocyte Fcγ Receptors In The Prothrombotic State Of Heparin Induced Thrombocytopenia (HIT)
- Author
-
Daria Madeeva, Valerie Tutwiler, Vincent Hayes, Douglas B. Cines, Lubica Rauova, Shahara Bailey, and Mortimer Poncz
- Subjects
Chemistry ,Monocyte ,Immunology ,Cell Biology ,Hematology ,CD16 ,medicine.disease ,Biochemistry ,Molecular biology ,Tissue factor ,medicine.anatomical_structure ,Heparin-induced thrombocytopenia ,Blocking antibody ,medicine ,Platelet ,Platelet activation ,Platelet factor 4 - Abstract
HIT is an antibody-mediated disorder characterized by thrombocytopenia and thrombosis. Activation of platelet via FcγRIIA by HIT antibodies complexed to surface-bound platelet factor 4 (PF4) contributes to the prothrombotic state. However, using an in vitro microfluidic whole human blood model of HIT, we have found through depletion and repletion studies that activation of monocytes through Syk-kinase is a key step in generating a prothrombotic milieu. Here we define the Fcγ receptor(s) upstream of Syk that mediate the thrombotic signal in monocytes. Monocytes isolated from normal healthy volunteers were incubated with 50 µg/ml of blocking antibodies against FcγRIIA (CD32, clone IV.3) and/or against FcγRI (CD64, clone 10.1) or against FcγRIII (CD16, clone 3G8), washed to remove unbound antibody and added to monocyte depleted-whole blood. These monocyte-repleted samples were then stimulated with PF4 (10 µg/ml) and the HIT like monoclonal antibody KKO (50 µg/ml) for 30 min. After recalcification (5 mmol CaCl2), samples were perfused over a von Willebrand factor-coated BioFlux microfluidic channel at a shear stress of 20 dyne/cm2 at 37°C for 15 min. Platelet adhesion was quantified by fluorescence microscopy after adding Calcein-AM (3 µM), and fibrin was visualized by adding Alexa 561-labeled fibrinogen (1.5 μg/ml) to the whole blood prior to the perfusion. Selective inhibition of FcγRIIA on monocytes led to an ∼40% inhibition of fibrin deposition and comparable reduction in the formation of “coated” platelets relative to samples repleted with non-inhibited monocytes. Flow cytometry studies showed that these observations were not due to leaching of IV.3 antibody off the monocytes with subsequent blocking of platelet FcγRIIA. In contrast, selective blockade of FcγRI or FcγRIII in depletion/repletion studies or in whole blood did not significantly reduce platelet adhesion, formation of coated platelets, or fibrin accumulation. However, blocking FcγRI did decrease tissue factor (TF) activity on monocytes stimulated with PF4 and KKO and this effect was additive to FcγRIIA inhibition. In summary, our data show that monocyte-bound HIT IgG antibodies contribute to the prothrombotic state by activating FcγRIIA directly and indirectly by generating TF though FcγRI. We speculate that this activation of monocytes contributes to platelet activation and monocyte microparticle formation demonstrated previously. Drugs that target FcγRI and FcγRIIA on monocytes may help prevent thrombosis in HIT without causing platelet dysfunction or increasing the risk of bleeding. Disclosures: No relevant conflicts of interest to declare.
- Published
- 2013
50. Aryl Hydrocarbon Receptor (AhR) Antagonist Stemregenin 1 (SR1) Enhances in Vitro- and in Vivo-Derived Platelets (PLTs) From Human Megakaryocytes (MKs)
- Author
-
Mortimer Poncz, John D. Crispino, Yuhuan Wang, Patrick J. Paddison, Deborah L. French, Lin Lu, Xiaoji Chen, Vincent Hayes, Stella T. Chou, Rudy Fuentes, Qiang Jeremy Wen, and Beverly Torok-Storb
- Subjects
medicine.medical_treatment ,Immunology ,Cell Biology ,Hematology ,Biology ,Biochemistry ,Peripheral blood mononuclear cell ,Andrology ,Haematopoiesis ,Cytokine ,medicine.anatomical_structure ,In vivo ,medicine ,Platelet ,Thrombopoiesis ,Bone marrow ,Ex vivo - Abstract
Abstract 3450 Our goal is to generate sufficient PLTs from ex vivo-generated MKs for clinical utility in PLT transfusions. A critical step in this process begins with ex vivo-generated hMKs and deriving clinically relevant PLTs. We reported that infused mature, high-ploidy murine (m) MKs derived from fetal liver (FL) cells increased PLT counts in recipient mice in a clinically relevant fashion, thus avoiding the need to generate ex vivo functional PLTs. We examined whether this strategy applies to hMKs derived from FL cells (gestational age, 17–21 weeks) and bone marrow (BM) cells in a xeno-transfusion model using immunodeficient NOD/SCID/IL-2Rγcnull (NSG) mice. Infused hPLTs isolated from blood had a half-life (T1/2) of 10 hours (hrs), compared to 24 hrs for infused murine PLTs. The hPLTs were functional in NSG mice as demonstrated by their incorporation into growing thrombi in situ. Both hFL hematopoietic mononuclear cells and hBM-CD34+ cells were cultured in serum-free media supplemented with optimized cytokine cocktails to generate hMKs. In contrast to the murine studies where the FL cell-derived mMKs were the most efficient source of derived mPLTs, FL cell-derived hMKs had low ploidy (0% ≥ 8N ploidy), gave rise to ∼16 PLTs/infused hMK, and had a short T1/2 (6 hrs). In contrast, 17% of hBM cell-derived MKs had a ploidy of ≥ 8N, and after infusion into NSG mice, resulted in a wave of MKs transiently entrapped in the pulmonary microvasculature and then over ∼0.5–3 hrs released PLTs with a T1/2 of 10 hrs, comparable to infused hPLTs. Maximally, we achieved a level of 5% of circulating total PLTs being derived from human cells with ∼32 PLTs/infused hMK. These hPLTs were normal in size, displayed normal levels of surface markers, were functional, and incorporated into growing thrombi. One strategy to increase hPLT yield is to expose developing MKs to drugs reported to increase MK maturation, thrombopoiesis, and/or facilitate hematopoietic progenitor cell expansion. Such drugs include dimethylfasudil (diMF) (an inhibitor of several kinases involved in polyploidization), UNC0638 (a G9a histone methyltransferase inhibitor), SR1 (an AhR antagonist), and nicotinamide (a sirtuin histone/protein deacetylases inhibitor). Although diMF promoted size and polyploidization of hMKs, diMF markedly worsened yield of PLTs/infused hMK and decreased PLTs T1/2 in vivo. UNC0638 led to significant cell expansion, but lowered hMKs ploidy and PLTs/infused hMK yield. Nicotinamide increased maturation, size and polyploidization of hMKs, but PLT release following MK infusion needs further study. Of note, SR1 that has been reported to promote the expansion of human HSC, not only increased size and ploidy of hMKs, but also hPLT release in vitro and in vivo. SR1-treated hMKs resulted in a 3-fold increased yield of normal size, T1/2 and functional PLTs/infused hMK compared to a DMSO-treated control. In summary, like mMKs, infused hMKs into mice release PLTs in the pulmonary vasculature though at a lower efficiency. Released hPLTs were functional and T1/2 was as expected. diMF enhanced MK ploidy, but worsened PLT yield and T1/2, while an AhR antagonist SR1 that also improved MK ploidy appears to markedly enhance yield of PLT/infused hMK, while maintaining T1/2. The ability of SR1 to enhance PLT release from induced pluripotent stem cells (iPSCs)-derived MKs remains to be tested, but this drug appears to be a strong candidate for a therapeutic strategy to take ex vivo-grown hMKs and generate PLTs in clinical relevant numbers. Disclosures: No relevant conflicts of interest to declare.
- Published
- 2012
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.